EP1929271A1 - Device for on-line process control during the production of emulsions or dispersions - Google Patents
Device for on-line process control during the production of emulsions or dispersionsInfo
- Publication number
- EP1929271A1 EP1929271A1 EP05792460A EP05792460A EP1929271A1 EP 1929271 A1 EP1929271 A1 EP 1929271A1 EP 05792460 A EP05792460 A EP 05792460A EP 05792460 A EP05792460 A EP 05792460A EP 1929271 A1 EP1929271 A1 EP 1929271A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- stirring
- emulsions
- vessel
- emulsion
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 121
- 239000006185 dispersion Substances 0.000 title claims abstract description 79
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 30
- 238000004886 process control Methods 0.000 title claims abstract description 12
- 238000003756 stirring Methods 0.000 claims abstract description 57
- 239000000523 sample Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 16
- 238000007792 addition Methods 0.000 claims description 13
- 238000005259 measurement Methods 0.000 claims description 11
- 239000007858 starting material Substances 0.000 claims description 5
- 238000010292 electrical insulation Methods 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 3
- 238000005496 tempering Methods 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
- -1 cerotyl alcohol Chemical compound 0.000 description 30
- 239000012071 phase Substances 0.000 description 29
- 239000000203 mixture Substances 0.000 description 19
- 239000000049 pigment Substances 0.000 description 19
- 150000002148 esters Chemical class 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000003995 emulsifying agent Substances 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 13
- 150000002632 lipids Chemical class 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 150000002191 fatty alcohols Chemical class 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 239000000787 lecithin Substances 0.000 description 7
- 235000010445 lecithin Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000001993 wax Substances 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 238000000265 homogenisation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920000223 polyglycerol Polymers 0.000 description 5
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 150000002314 glycerols Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000002800 charge carrier Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 235000004443 Ricinus communis Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005193 avobenzone Drugs 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 2
- YVHXHNGGPURVOS-SBTDHBFYSA-N fluprednidene Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](C(=C)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 YVHXHNGGPURVOS-SBTDHBFYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 238000011020 pilot scale process Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001987 poloxamine Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- KQMVAGISDHMXJJ-UHFFFAOYSA-N prunetin Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1OC=C2C1=CC=C(O)C=C1 KQMVAGISDHMXJJ-UHFFFAOYSA-N 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 150000003890 succinate salts Chemical class 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- TYWMIZZBOVGFOV-UHFFFAOYSA-N tetracosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCO TYWMIZZBOVGFOV-UHFFFAOYSA-N 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 229960000832 tromantadine Drugs 0.000 description 2
- UXQDWARBDDDTKG-UHFFFAOYSA-N tromantadine Chemical compound C1C(C2)CC3CC2CC1(NC(=O)COCCN(C)C)C3 UXQDWARBDDDTKG-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 1
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- ZDRRIRUAESZNIH-BZGUUIOASA-N (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-13-[(2s)-butan-2-yl]-10-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]- Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZDRRIRUAESZNIH-BZGUUIOASA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- FJIKWRGCXUCUIG-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C([C@H](O)N=1)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-HNNXBMFYSA-N 0.000 description 1
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
- QHZLMUACJMDIAE-SFHVURJKSA-N 1-hexadecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO QHZLMUACJMDIAE-SFHVURJKSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- ZXDDPOHVAMWLBH-UHFFFAOYSA-N 2,4-Dihydroxybenzophenone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 ZXDDPOHVAMWLBH-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- ORWUQAQITKSSRZ-UHFFFAOYSA-N 2-hydroxyethyl 4-[bis[2-(2-hydroxyethoxy)ethyl]amino]benzoate Chemical compound OCCOCCN(CCOCCO)C1=CC=C(C(=O)OCCO)C=C1 ORWUQAQITKSSRZ-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- NLJVXZFCYKWXLH-DXTIXLATSA-N 3-[(3r,6s,9s,12s,15s,17s,20s,22r,25s,28s)-20-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,22,25-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,18,21,24,27-nonaoxo-12-propan-2-yl-1,4,7,10,13,16,19,23,26-nonazabicyclo[26.3.0]hentriacontan Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 NLJVXZFCYKWXLH-DXTIXLATSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- ATEFPOUAMCWAQS-UHFFFAOYSA-N 7,8-dihydroxycoumarin Chemical compound C1=CC(=O)OC2=C(O)C(O)=CC=C21 ATEFPOUAMCWAQS-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 108010091893 Cosyntropin Proteins 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 108010024118 Hypothalamic Hormones Proteins 0.000 description 1
- 102000015611 Hypothalamic Hormones Human genes 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 description 1
- NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- AQRNEKDRSXYJIN-IRFILORWSA-N Oregonin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H](CC(=O)CCC=1C=C(O)C(O)=CC=1)CCC1=CC=C(O)C(O)=C1 AQRNEKDRSXYJIN-IRFILORWSA-N 0.000 description 1
- 108010012215 Ornipressin Proteins 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- QHZLMUACJMDIAE-UHFFFAOYSA-N Palmitic acid monoglyceride Natural products CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 102400000160 Thymopentin Human genes 0.000 description 1
- 101800001703 Thymopentin Proteins 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 108010021006 Tyrothricin Proteins 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- 108010047196 Urofollitropin Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000552 alclometasone Drugs 0.000 description 1
- FJXOGVLKCZQRDN-PHCHRAKRSA-N alclometasone Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O FJXOGVLKCZQRDN-PHCHRAKRSA-N 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229960003831 articaine Drugs 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 229960002526 bamipine Drugs 0.000 description 1
- VZSXTYKGYWISGQ-UHFFFAOYSA-N bamipine Chemical compound C1CN(C)CCC1N(C=1C=CC=CC=1)CC1=CC=CC=C1 VZSXTYKGYWISGQ-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960004374 befunolol Drugs 0.000 description 1
- ZPQPDBIHYCBNIG-UHFFFAOYSA-N befunolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1OC(C(C)=O)=C2 ZPQPDBIHYCBNIG-UHFFFAOYSA-N 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 229940111759 benzophenone-2 Drugs 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- 150000001565 benzotriazoles Chemical class 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- WXNRYSGJLQFHBR-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O WXNRYSGJLQFHBR-UHFFFAOYSA-N 0.000 description 1
- HHBIQTAAJCSNCD-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone;bis(2-hydroxy-4-methoxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O.OC1=CC(OC)=CC=C1C(=O)C1=CC=C(OC)C=C1O HHBIQTAAJCSNCD-UHFFFAOYSA-N 0.000 description 1
- SODJJEXAWOSSON-UHFFFAOYSA-N bis(2-hydroxy-4-methoxyphenyl)methanone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=C(OC)C=C1O SODJJEXAWOSSON-UHFFFAOYSA-N 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 229960003051 brotizolam Drugs 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229960000330 bupranolol Drugs 0.000 description 1
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000002302 calcium metabolism regulator Substances 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- CFOYWRHIYXMDOT-UHFFFAOYSA-N carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 description 1
- 229960001704 carbimazole Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- FCSHDIVRCWTZOX-DVTGEIKXSA-N clobetasol Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O FCSHDIVRCWTZOX-DVTGEIKXSA-N 0.000 description 1
- 229960004299 clocortolone Drugs 0.000 description 1
- YMTMADLUXIRMGX-RFPWEZLHSA-N clocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O YMTMADLUXIRMGX-RFPWEZLHSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960004414 clomethiazole Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960002219 cloprednol Drugs 0.000 description 1
- YTJIBEDMAQUYSZ-FDNPDPBUSA-N cloprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C=C(Cl)C2=C1 YTJIBEDMAQUYSZ-FDNPDPBUSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000008271 cosmetic emulsion Substances 0.000 description 1
- ZOEFCCMDUURGSE-SQKVDDBVSA-N cosyntropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 ZOEFCCMDUURGSE-SQKVDDBVSA-N 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- WTYGAUXICFETTC-UHFFFAOYSA-N cyclobarbital Chemical compound C=1CCCCC=1C1(CC)C(=O)NC(=O)NC1=O WTYGAUXICFETTC-UHFFFAOYSA-N 0.000 description 1
- 229960004138 cyclobarbital Drugs 0.000 description 1
- LMKPHJYTFHAGHK-UHFFFAOYSA-N cyclodrine Chemical compound C1CCCC1(O)C(C(=O)OCCN(CC)CC)C1=CC=CC=C1 LMKPHJYTFHAGHK-UHFFFAOYSA-N 0.000 description 1
- 229950000158 cyclodrine Drugs 0.000 description 1
- MKNXBRLZBFVUPV-UHFFFAOYSA-L cyclopenta-1,3-diene;dichlorotitanium Chemical compound Cl[Ti]Cl.C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 MKNXBRLZBFVUPV-UHFFFAOYSA-L 0.000 description 1
- 229960001815 cyclopentolate Drugs 0.000 description 1
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- YBGKGTOOPNQOKH-UHFFFAOYSA-N daphnetin Natural products OC1=CC=CC2=C1OC(=O)C=C2O YBGKGTOOPNQOKH-UHFFFAOYSA-N 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960005081 diclofenamide Drugs 0.000 description 1
- GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 1
- 229960004154 diflorasone Drugs 0.000 description 1
- WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 description 1
- 229960004091 diflucortolone Drugs 0.000 description 1
- OGPWIDANBSLJPC-RFPWEZLHSA-N diflucortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O OGPWIDANBSLJPC-RFPWEZLHSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- LUZRJRNZXALNLM-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 LUZRJRNZXALNLM-JGRZULCMSA-N 0.000 description 1
- 229960000465 dihydrotachysterol Drugs 0.000 description 1
- ILYCWAKSDCYMBB-OPCMSESCSA-N dihydrotachysterol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1/C[C@@H](O)CC[C@@H]1C ILYCWAKSDCYMBB-OPCMSESCSA-N 0.000 description 1
- MVMQESMQSYOVGV-UHFFFAOYSA-N dimetindene Chemical compound CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 MVMQESMQSYOVGV-UHFFFAOYSA-N 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- XACKNLSZYYIACO-DJLDLDEBSA-N edoxudine Chemical compound O=C1NC(=O)C(CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XACKNLSZYYIACO-DJLDLDEBSA-N 0.000 description 1
- 229960002030 edoxudine Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 229960000655 ensulizole Drugs 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- 229960004697 enzacamene Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1 XCGSFFUVFURLIX-VFGNJEKYSA-N 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- IAJNXBNRYMEYAZ-UHFFFAOYSA-N ethyl 2-cyano-3,3-diphenylprop-2-enoate Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC)C1=CC=CC=C1 IAJNXBNRYMEYAZ-UHFFFAOYSA-N 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 229960004585 etidronic acid Drugs 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 235000011990 fisetin Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960002011 fludrocortisone Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229950008509 fluocortin butyl Drugs 0.000 description 1
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 description 1
- 229960003973 fluocortolone Drugs 0.000 description 1
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 229960003704 framycetin Drugs 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000008466 glycitein Nutrition 0.000 description 1
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 1
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 229960003242 halofantrine Drugs 0.000 description 1
- 229960002475 halometasone Drugs 0.000 description 1
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229960000857 homatropine Drugs 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 229940043650 hypothalamic hormone Drugs 0.000 description 1
- 239000000601 hypothalamic hormone Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- USSIQXCVUWKGNF-QGZVFWFLSA-N levomethadone Chemical compound C=1C=CC=CC=1C(C[C@@H](C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-QGZVFWFLSA-N 0.000 description 1
- 229960002710 levomethadone Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003019 loprazolam Drugs 0.000 description 1
- UTEFBSAVJNEPTR-RGEXLXHISA-N loprazolam Chemical compound C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229960004033 lormetazepam Drugs 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229960003729 mesuximide Drugs 0.000 description 1
- 229960004650 metergoline Drugs 0.000 description 1
- WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
- 229960002803 methaqualone Drugs 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 229960002683 methohexital Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001186 methysergide Drugs 0.000 description 1
- 229960002704 metipranolol Drugs 0.000 description 1
- BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- CLJDBQVBSMXSTP-UHFFFAOYSA-N octan-3-yl 2-hydroxybenzoate Chemical class CCCCCC(CC)OC(=O)C1=CC=CC=C1O CLJDBQVBSMXSTP-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- RBFTVHQXEPVALV-ZPQCQBRUSA-N oregonin Natural products O[C@@H]1O[C@H](O[C@H](CCc2ccc(O)c(O)c2)CC(=O)CCc3ccc(O)c(O)c3)[C@@H](O)[C@H](O)[C@H]1O RBFTVHQXEPVALV-ZPQCQBRUSA-N 0.000 description 1
- 229960004571 ornipressin Drugs 0.000 description 1
- MUNMIGOEDGHVLE-LGYYRGKSSA-N ornipressin Chemical compound NC(=O)CNC(=O)[C@H](CCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 MUNMIGOEDGHVLE-LGYYRGKSSA-N 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 229960003502 oxybuprocaine Drugs 0.000 description 1
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- SBUQZKJEOOQSBV-UHFFFAOYSA-N pholedrine Chemical compound CNC(C)CC1=CC=C(O)C=C1 SBUQZKJEOOQSBV-UHFFFAOYSA-N 0.000 description 1
- 229960001029 pholedrine Drugs 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 229940081510 piroctone olamine Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229960004572 pizotifen Drugs 0.000 description 1
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960002794 prednicarbate Drugs 0.000 description 1
- FNPXMHRZILFCKX-KAJVQRHHSA-N prednicarbate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O FNPXMHRZILFCKX-KAJVQRHHSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960001917 prednylidene Drugs 0.000 description 1
- WSVOMANDJDYYEY-CWNVBEKCSA-N prednylidene Chemical group O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](C(=C)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WSVOMANDJDYYEY-CWNVBEKCSA-N 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 229950011219 propipocaine Drugs 0.000 description 1
- STHAHFPLLHRRRO-UHFFFAOYSA-N propipocaine Chemical compound C1=CC(OCCC)=CC=C1C(=O)CCN1CCCCC1 STHAHFPLLHRRRO-UHFFFAOYSA-N 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 229960002924 proxibarbal Drugs 0.000 description 1
- VNLMRPAWAMPLNZ-UHFFFAOYSA-N proxibarbal Chemical compound CC(O)CC1(CC=C)C(=O)NC(=O)NC1=O VNLMRPAWAMPLNZ-UHFFFAOYSA-N 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 239000002795 scorpion venom Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- FKJIJBSJQSMPTI-CAOXKPNISA-M sodium;(4r)-4-[(5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C FKJIJBSJQSMPTI-CAOXKPNISA-M 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
- 229940035023 sucrose monostearate Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- 229960003188 temazepam Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960001423 tetracosactide Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
- 229960004517 thymopentin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 229960003281 tyrothricin Drugs 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229960004371 urofollitropin Drugs 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008307 w/o/w-emulsion Substances 0.000 description 1
- 239000010456 wollastonite Substances 0.000 description 1
- 229910052882 wollastonite Inorganic materials 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N11/00—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties
- G01N11/10—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties by moving a body within the material
- G01N11/14—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties by moving a body within the material by using rotary bodies, e.g. vane
Definitions
- the invention relates to a device for in-line process control in the production of emulsions or dispersions, the use of such a device for determining suitable process parameters for the preparation of emulsions or dispersions and a method for determining suitable process parameters for the preparation of emulsions or dispersions.
- the preparation of emulsions and dispersions is usually carried out batchwise in stirred reactors.
- the required amounts of the starting materials are metered into a mixing vessel and emulsified or dispersed with a high degree of stirring.
- high-performance stirrers are used which allow the generation of cavitation forces.
- high pressure homogenization is often performed.
- a control of the emulsions produced and dispersions and of the process usually takes place only on the finished product of the corresponding mixture batch.
- a continuous review of the manufacturing process is usually not possible. Since the product can be analyzed only after completion of the corresponding batch mixture, the setting of advantageous or optimal process parameters for the preparation of the emulsions and dispersions is difficult. An optimized production is - if any - only consuming possible in numerous iterations.
- the determination of the interdependence of process parameters and products thus obtained, for example on the Rlickeintrag, the temperature and the nature of the addition of the ingredients is not possible by known methods.
- the object of the present invention is to provide an apparatus for in-line process control in the preparation of emulsions or dispersions, and a method for determining suitable process parameters for the preparation of emulsions or dispersions, wherein the disadvantages of the devices known from the prior art and Procedures should be avoided.
- an apparatus for in-line process control in the production of emulsions or dispersions comprising a vessel for receiving an emulsion or dispersion, arranged in the vessel agitator for stirring entry into the emulsion or dispersion, a device for continuous Measuring the stirring entry, measuring probes arranged in the vessel for the continuous measurement of the temperature and the conductivity of the emulsion or dispersion, and a recording device for the continuous recording of the stirring entry, the temperature and the conductivity.
- the device can be used, for example, for the discontinuous production of emulsions and dispersions on a laboratory, pilot scale or production scale.
- the object is further achieved by the use of such a device for determining suitable process parameters for the preparation of emulsions or dispersions.
- the object is further achieved by a method for determining suitable process parameters for the preparation of emulsions or dispersions, in which, in a device as described above, the starting materials of the emulsions or dispersions are introduced jointly or separately into the vessel and mixed with stirring and the stirring entry, the conductivity and the temperature are measured continuously and, depending on the measured values obtained, if appropriate, the stirring input and / or the temperature of the vessel are changed.
- the device according to the invention first comprises a vessel for receiving an emulsion or dispersion or ingredients of an emulsion or dispersion and for receiving measuring probes for the continuous measurement of the temperature and conductivity of the emulsion or dispersion.
- the measurement of temperature and conductivity can be done in a combined probe.
- the vessel is designed so that it can accommodate a stirring tool.
- the vessel may be open on one side (top) as in a stirred reactor. This is the usual case. It is also possible to design the vessel closed on all sides, with the exception of inlets and outlets and stirrer feedthroughs or feedthroughs for analytical sensors, the vessel is closed.
- the stirrer allows mechanical stirring into the emulsion or dispersion.
- the stirring tool according to an embodiment of the invention is designed so that it works without generating cavitation forces and without high-pressure homogenization.
- suitable stirring elements are arranged on a stirrer axis which is rotated.
- the stirring tool then has at least one stirring element driven by a stirring motor via a rotated agitator axis.
- the stirring tool may be so-called rotor / stator systems in which a rotor is moved by motor-driven operation.
- the stator is usually the housing, which may be provided with internals such as crushers.
- Suitable stirrers are, for example, paddle stirrers, which may optionally be provided with scrapers.
- stirrers such as planetary stirrers, anchor stirrers, bar stirrers, propellers, blade stirrers, dissolver disks or Intermig can be used as an alternative.
- Other suitable stirrer configurations are known to those skilled in the art.
- the stirring tool is preferably operated in such a way that the stirring entry into the emulsion or dispersion takes place without generation of cavitation forces and without high-pressure homogenization.
- a homogenizer may additionally be provided in (for example near the bottom) or on the mixing vessel.
- the vessel can also have a circulation in which, for example, a homogenizer can be provided.
- grinding tools such as grinding beads or balls may also be present in the vessel. Suitable grinding tools are known in the art.
- the vessel can have any suitable geometry, as long as it allows a suitable mixing of the flowable substances or mixtures or the phases of the emulsions and dispersions to be prepared. Suitable geometries are known to the person skilled in the art.
- the mixing vessel preferably has an essentially cylindrical shape on the inside, the axis of the stirring tool lying in the cylinder axis.
- the arrangement of the measuring probe or probes can be provided directly in the cylindrical space of the vessel. It is also possible to provide two cylindrical vessels which are parallel and spaced from each other and which communicate with each other at the lower end so as to mix in both of them by means of stirring can be made cylindrical vessels. Such an embodiment is described in the attached Figures 1 to 3.
- FIGS. 1 and 2 show mutually perpendicular cross-sectional views through the vessel according to the invention.
- FIG. 3 shows a plan view of the vessel.
- Figure 4 shows the schematic structure of the isolated stirrer.
- FIG. 5 shows the schematic structure of the device according to the invention.
- FIGS. 6 to 10 show plots of the conductivity versus the measuring time or temperature. The figures will be explained in more detail below.
- FIG. 1 and FIG. 2 show cross sections through the vessel provided in the device according to the invention.
- the vessel has a jacket for temperature control, through which a temperature control liquid can be passed.
- the supply and discharge for the temperature control, in particular coolant or heating means are shown left top and bottom right.
- the corresponding inlets and outlets are also shown in Figure 2 below and above as (dashed) circles, while they are recognizable in Figure 3 left and right of the vessel.
- two cylindrical recesses of different diameters are provided in the cooling / heating jacket, which are interconnected in the lower region. This is apparent in particular from FIG. In FIG. 2, to the left, the smaller diameter cylindrical aperture and, to the right, the larger diameter cylindrical aperture, which are interconnected in the lower region, are shown.
- the left port accepts the temperature and conductivity probe, while the right port picks up the agitator. Both the probe and the stirring tool are inserted from above. The corresponding openings are shown in Figure 3 from above. During operation, mixing of the emulsions / dispersions is achieved by the stirring tool, so that the mixed emulsion / dispersion also flows past the measuring probe in the left-hand cylindrical opening.
- the (mixed) vessel used according to the invention can be selected in size according to the respective practical requirements.
- the internal volume (free volume) of the (mixed) vessel is preferably 50 ml to 10 l, more preferably 100 ml to 5 l, in particular 300 to 1000 ml.
- the internal volume is preferably 5 to 100 ml, more preferably 10 to 50 1.
- the volume or Take up capacity preferably more than 20 tons, for example more than 50 tons.
- Recesses are for example 15 and 48 mm. Including the entire vessel
- the jacket has an outer diameter of 92 mm.
- the outer diameter including shell is preferably 50 to 350 mm.
- the diameter of the larger cylindrical opening is preferably 25 to 300 mm.
- FIGS. 1 to 3 show a temperature control jacket through which a temperature control medium flows.
- suitable devices for controlling the temperature of the vessel may be provided.
- the device according to the invention is used in particular for the discontinuous production of emulsions or dispersions.
- the container shown is charged with the ingredients of the emulsions or dispersions through the openings arranged above, and the finished dispersion or emulsion is also removed through this opening.
- Other geometries of the vessel, the loading and unloading are known in the art.
- the device for in-line process control can also be integrated into already existing conventional stirring vessels in pilot plant or production scale, for example subsequently.
- the stirrer axis preferably has an electrical insulation in its course in such a way that the stirring element and the stirring motor are electrically insulated from one another.
- An exemplary embodiment of this insulation is shown schematically in FIG. R stands for the stirrer axis, S stands for the stirrer axis mounted shrink tubing made of non-conductive plastic material, and M is a pushed onto the shrink tubing metal sleeve.
- FIG. 5 shows the schematic structure of the entire device by way of example.
- the stirring tool Ru has a magnetic belt Ma, which in turn serves as a signal generator for a rotational speed sensor Dr. From the stirring tool, the stirrer axis protrudes into the vessel. Furthermore, a measuring probe for measuring the temperature and conductivity Le also protrudes into the vessel. Both the speed sensor and the measuring probe are connected to a control and recording device St, which in turn is controlled by a computer Re, and transmits the data to the computer.
- a monitor Mo can be used to check the control of the temperature and speed as well as the measurement of the parameters.
- an input unit such as a keyboard, with which the computer and the control unit can be controlled. Usually also output media are provided for the information.
- Both the control of the stirring motor and optionally of pumps or metering devices for the ingredients of the emulsions or dispersions and the measured value recording can be controlled via a central computer.
- the evaluation of the obtained measured values (parameters) preferably also takes place via a central computer.
- the continuous recording of the stirring, the temperature and the conductivity can be done with the help of the computer, but also via other suitable media such as printers or plotters.
- the stirring entry and optionally the temperature of the vessel are computer controlled, and the continuous recording and optionally evaluation of the Rlickeintrags, the temperature and the conductivity is also computerized.
- emulsions and dispersions can be examined for their temperature and shear behavior. Furthermore, critical parameters can be determined and optimized in the preparation of the emulsions and dispersions. In the preparation of dispersions, the pigment addition is usually critical. With the device according to the invention it can be determined in a simple manner how much pigment can be introduced into an emulsion and when the pigment addition ideally takes place. Furthermore, the training a LC phase in an emulsion are determined time-resolved. Different stirrer speeds can be used to determine scaling-up parameters during production. The formation of LC gel networks can be determined by the conductivity at different temperatures. Similarly, the influence of low or high speeds can be observed here.
- the progress of blending or emulsification or dispersion at any stage of the process and at any stage in the process can be accomplished in real time with no time delay, ie. H. be analyzed in-line, and in the stirred tank itself, so that appropriate measures such as adjustment of the stirring, the temperature, or addition (time, speed, amount) of emulsion or dispersion components, can be controlled to the production of emulsions or dispersions to optimize.
- the continuous determination of one or more of the mentioned parameters allows a continuous process control and a continuous control of the composition of the emulsion or dispersion.
- the quality assurance in the production is thus considerably improved or simplified. This is particularly important in pharmaceutical products of high importance.
- the device according to the invention allows, for example, the ideal in-line process control for the preparation of oil-in-water emulsions or water-based dispersions.
- important parameters such as peripheral speed of the stirrer, temperature of the emulsion / dispersion and conductivity of the emulsion / dispersion are continuously recorded automatically.
- the conductivity data which are determined during the emulsification process, allow a very good interpretation of the emulsion structure as a function of temperature and stirring intensity.
- the conductivity of an emulsion / dispersion is directly related to its degree of dispersion, viscosity and structure.
- FIG. 6 shows a pigment addition to an emulsion. At the points marked with the arrows, 2 g of pigment were added to the emulsion with stirring. The conductivity was determined as a function of the measuring time. The curve indicates after which time an equilibrium is reached (slope of the curve approaches zero).
- the present invention allows the indirect measurement of pigment dispersion and the measurement of the amount of pigment that can be dispersed in an emulsion.
- the conductivity does not necessarily decrease with increasing degree of dispersion. Here it can also increase with increasing degree of dispersion.
- Phenomenon particularly occurs when ionogenic emulsifiers are used.
- Emulsifier increases the ion concentration in the water phase and thus the conductivity of the emulsion.
- a typical example of how the conductivity of an O / W emulsion stabilized by ionic emulsifiers increases is shown in FIG.
- Oil-in-water emulsions are often stabilized by liquid crystalline gel networks. These are formed depending on the melting point of the mixing emulsifiers in the temperature range below 60 ° C.
- FIG. 8 shows the determination of the critical gel network temperature during cooling. It is the conductivity as a function of the temperature applied. At low temperature there is a LC gel network. Preservatives are preferably added at these temperatures in which an LC gel network is present since smaller amounts are required for good efficacy. At the temperature at which the conductivity increases, the particle size can be reduced again by post-homogenization. About the transition temperature to the LC gel network also statements about the water resistance of, for example, sunscreen agents are possible. A transition at about 30 ° C means a non-waterproof composition.
- FIG. 9 shows the influence of the stirring speed on the required emulsification time.
- the conductivity is plotted as a function of the measuring time.
- a stirrer speed 3.15 m / s
- a stable emulsion forms after about 2000 s, while at a stirrer speed of 1.44 m / s more than 3000 s are required.
- stirrer speeds and thus scaling-up parameters can be determined.
- FIG. 10 shows the behavior of the LC gel network formation at different production temperatures. It is the conductivity as a function of the temperature applied.
- a first LC-gel network was made at 80 0 C, a second LC Gel network at 65 0 C.
- For the gel network produced at a higher temperature results in lower temperatures, a lower conductivity, as shown in Figure 10.
- the weight ratio of the phases is preferably in a range of 1:15 to 15: 1, preferably 1: 5 to 5: 1, preferably 1: 2 to 2: 1, especially 1: 1.5 to 1.5 : 1 chosen.
- the proportions by weight of the corresponding phases are preferably in this range.
- the microemulsion obtained by mixing the phases can be understood as a system of two interpenetrating networks, so that the microemulsion exhibits single-phase behavior.
- About the conductivity statements about the phase volume ratio are possible. By measuring the conductivity, it is therefore easy to determine changes in the emulsion composition or in the phase volumes.
- the process control is carried out in-line, for example on a production scale, for example up to the ton scale in the range of, for example, 1 to 20 tons of emulsion or dispersion, ie continuously during the manufacturing process.
- the temperature of the (mixed) Gefackedes and the supply of starting materials for the emulsions and dispersions can be computer controlled. All process parameters can be controlled and controlled via a central computer. The measured values supplied by the sensors are also preferably fed to the computer as described and evaluated computer-aided.
- the (mixed) vessel may be constructed of any suitable material.
- suitable inert materials are plastics, steels such as V2A or V4A steel or copper. Suitable materials or materials are known in the art.
- the selection of the stirring tool, the size of the (mixing) vessel and so on is carried out according to the practical requirements and is to be determined by simple preliminary tests.
- the device according to the invention can be inexpensively adapted to a variety of applications by selecting suitable stirring tools.
- the in-line process control according to the invention can also be integrated into known mixing vessels on a production scale.
- the apparatus and method of the present invention are applicable to a variety of emulsions or dispersions.
- emulsions according to the invention or multiple emulsions are prepared. Examples are OW emulsions, WO emulsions, PO emulsions, multiple emulsions, LC gels, liposomes or pearlescent concentrates.
- a wide variety of particle sizes are accessible in the emulsions.
- the active substance and the lipid-based active substance carrier and at least one emulsifier which forms lamellar structures can first be mixed at a temperature above the melting or softening point of the active ingredient carrier , In this case, a phase B is formed. Then, this phase B can be mixed with an aqueous phase A at a temperature above the melting or softening point of the active ingredient carrier.
- the active ingredient carrier particles used are lipid-based particles. These include lipids and lipid-like structures.
- suitable lipids are the mono-, di- and triglycerides of the saturated straight-chain fatty acids having 12 to 30 carbon atoms, such as lauric, myristic, palmitic, stearic, arachidic, behenic, lignoceric, cerotic, meleinic, as well as their esters with other polyhydric alcohols such as ethylene glycol , Propylene glycol, mannitol, sorbitol, saturated fatty alcohols having 12 to 22 carbon atoms, such as lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, arachidyl alcohol, behenyl alcohol, saturated wax alcohols having 24 to 30 carbon atoms, such as lignoceryl alcohol, ceryl alcohol, cerotyl alcohol, myrizyl alcohol.
- synthetic mono-, di- and triglycerides are used as individual substances or in the form of a mixture, for example in the form of a hard fat.
- Glycerol trifatty acid esters are, for example, glycerol trilaurate, glycerol trimyristate, glycerol palmitate, glycerol tristearate or glycerol tribehenate.
- Suitable waxes are, for example, cetyl palmitate and Cera Alba (bleached wax, DAB 9).
- Polysaccharides with or in individual cases or polyalkyl acrylates, polyalkyl cyanoacrylates, polyalkyl vinyl pyrrolidones, acrylic polymers, polylactic acids or polylactides can also be used as lipids.
- the amount of the active substance carrier particles, based on the total aqueous active ingredient carrier dispersion, is preferably 0.1 to 30% by weight, particularly preferably 1 to 10% by weight.
- dispersion stabilizers can be used. They may, for example, in amounts of 0.01 to 10 wt .-%, preferably 0.05 be used to 5 wt .-%.
- Suitable substances are surfactants, in particular ethoxylated sorbitan fatty acid esters, block polymers and block copolymers (such as poloxamers and poloxamines), polyglycerol ethers and esters, lecithins of various origins (for example egg or soya lecithin), chemically modified lecithins (for example hydrogenated lecithin) as well Phospholipids and sphingolipids, mixtures of lecithins with phospholipids, sterols (for example cholesterol and cholesterol derivatives and stigmasterol), esters and ethers of sugars or sugar alcohols with fatty acids or fatty alcohols (for example sucrose monostearate), sterically stabilizing substances such as poloxamers and poloxamines (polyoxyethylene-polyoxypropylene) Block polymers), ethoxylated sorbitan fatty acid esters, ethoxylated mono- and diglycerides, ethoxylated lipids and lipid
- viscosity-increasing substances such as cellulose ethers and esters (for example methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose), polyvinyl derivatives such as polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl acetate, alginates, polyacrylates (for example Carbopol), Xanthans and pectins.
- cellulose ethers and esters for example methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose
- polyvinyl derivatives such as polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl acetate, alginates, polyacrylates (for example Carbopol), Xanthans and pectins.
- aqueous phase A water, aqueous solutions or mixtures of water with water-miscible liquids such as glycerol or polyethylene glycol can be used.
- Further additional components for the aqueous phase are, for example, mannose, glucose, fructose, xylose, trehalose, mannitol, sorbitol, xylitol or other polyols, such as polyethylene glycol, and electrolytes, such as sodium chloride. These additional components can be used in an amount of 0.5 to 60, for example 1 to 30 wt .-%, based on the aqueous phase A.
- viscosity-increasing substances or charge carriers as described in EP-B-0 605 497.
- Emulsifiers that form lamellar structures can be natural or synthetic
- emulsifiers are the physiological bile salts such as sodium cholate,
- Sodium dehydrocholate, sodium deoxycholate, sodium glycocholate, sodium taurocholate Animal and plant phospholipids such as lecithins with their hydrogenated forms as well as polypeptides such as gelatin with their modified forms can also be used.
- Suitable synthetic surfactants are the salts of sulfosuccinic acid esters, polyoxyethylene acid betanesters, acid betanesters and sorbitan ethers, polyoxyethylene fatty alcohol ethers, polyoxyethylene stearate esters and corresponding blend condensates of polyoxyethylene-methopolyoxypropylene ethers, ethoxylated saturated glycerides, partial fatty acid glycerides and polyglycides.
- suitable surfactants are Biobase® EP and Ceralution® H.
- emulsifiers are also glycerol esters, polyglycerol esters, sorbitan esters, sorbitol esters, fatty alcohols, propylene glycol esters, alkylglucositesters, sugar esters, lecithin, silicone copolymers, wool wax and mixtures thereof or derivatives.
- Glycerol esters, polyglycerol esters, alkoxylates and fatty alcohols and isoalcohols can be derived, for example, from castor fatty acid, 12-hydroxystearic acid, isostearic acid, oleic acid, linoleic acid, linolenic acid, stearic acid, myristic acid, lauric acid and capric acid.
- succinates, amides or ethanolamides of the fatty acids may also be present.
- Particularly suitable fatty acid alkoxylates are the ethoxylates, propoxylates or mixed ethoxylates / propoxylates.
- Emulsifiers are also generally used to prepare the cosmetic emulsions according to the invention.
- suitable emulsifiers are glycerol esters, polyglycerol esters, sorbitan esters, sorbitol esters, fatty alcohols, propylene glycol esters, alkylglucoside esters, sugar esters, lecithin, silicone copolymers, wool wax and their mixtures and derivatives.
- Glycerol esters, polyglycerol esters, alkoxylates and fatty alcohols and isoalcohols can be derived, for example, from castor fatty acid, 12-hydroxystearic acid, isostearic acid, oleic acid, linoleic acid, linolenic acid, stearic acid, myristic acid, mauric acid and capric acid.
- succinates, amides or ethanolamides of the fatty acids may also be present.
- Particularly suitable fatty acid alkoxylates are the ethoxylates, propoxylates or mixed ethoxylates / propoxylates. It is also possible to use emulsifiers which form lamellar structures.
- emulsifiers examples include the physiological bile salts such as sodium cheolate, sodium dehydrocheolate, sodium deoxycheolate, sodium glycochelate, sodium taurochalate.
- physiological bile salts such as sodium cheolate, sodium dehydrocheolate, sodium deoxycheolate, sodium glycochelate, sodium taurochalate.
- Animal and vegetable phospholipids like Lecithins with their hydrogenated forms as well as polypeptides such as gelatin with their modified forms can also be used.
- Suitable synthetic surfactants are the salts of sulfosuccinic, Polyoxiethylenchurebethanester, pressureurebethanester and sorbitan, Polyoxiethylenfettalkoholether, Polyoxiethylenstearinklareester and corresponding mixture condensates of Polyoxiethylen-methpolyoxipropylenethern, ethoxylated saturated glycerides, partial fatty acid glycerides and polyglycides.
- suitable surfactants are Biobase ® EP and Ceralution ® H.
- Lipids and emulsifiers are preferably used in a weight ratio of 50: 1 to 2: 1, preferably 15: 1 to 30: 1.
- the pharmaceutical, cosmetic and / or food-technological active ingredients are, based on the phase B, preferably used in an amount of 0.1 to 80 wt .-%, particularly preferably 1 to 10 wt .-%.
- Analgesics / antirheumatics such as morphine, copdein, piritamide, fentanyl and fentanyl derivatives, levomethadone, tramadol, diclofenac, ibuprofen, indomethacin, naproxen, piroxicam, penicillamine;
- Antiallergic agents such as pheniramine, dimetinden, terfenadine, asternizole, loratidine, doxylamine, meclozin, bamipin, clemastine;
- Antibiotics / chemotherapeutics such as polypetid antibiotics such as colistin, polymyxin B, teicplanin, vancomycin;
- Antimalarials such as quinine, halofantrine, mefloquine, chloroquine, antivirals such as ganciclovir, foscarnet, zidovudine, acyclovir and others such as daps
- Antimetabolites such as cytarabine, fluorouracil, methotrexate, mercaptopurine, tioguanine, alkaloids such as vinblastine, vincristine, vindesine; Antibiotics such as aclarubicin, bleomycin, dactinomycin, daunorubicin, epirubicin, idarubicin, mitomycin, plicamycin,
- Complexes of subgroup elements such as carboplatin, cisplatin and metallocene compounds such as titanocene dichloride amsacrine, dacarbazine, estramustine, etoposide, hydroxycarbamide, mitoxynthrone, procarbazine, temiposide, alkylamidophospholipids (described in JM Zeidler, F. Emling, W. Zimmermann and HJ Roth, Archiv der Pharmazie, 324 (1991), 687)
- subgroup elements for example, Ti, Zr, V, Nb, Ta, Mo, W, Pt
- metallocene compounds such as titanocene dichloride amsacrine, dacarbazine, estramustine, etoposide, hydroxycarbamide, mitoxynthrone, procarbazine, temiposide, alkylamidophospholipids (described in JM Zeidler, F. Emling, W. Zimmermann and HJ Roth, Archiv
- Etherlipids such as hexadecylphosphocholine, dmofosine and analogs described in R. Zeisig, D. Arndt and H. Brachwitz, Pharmacy 45 (1990), 809-818.
- Suitable active ingredients are, for example, also dichlorphenac, ibuprofen, acetylsalicylic acid, salicylic acid, erythromycin, ketoprofen, cortisone, glucocorticoids.
- cosmetic active ingredients which are particularly susceptible to oxidation or hydrolysis, for example polyphenols.
- Catechins such as epicatechin, epicatechin-3-gallate, epigallocatechin, epigallocatechin-3-gallate
- flavonoids such as luteolin, apigenin, rutin, quercitin, fisetin, kaempherol, rhametin
- isoflavones such as genistein, daidzein, glycitein, Prunetin
- coumarins such as daphnetin, umbelliferone
- emodin emodin
- resveratrol oregonin.
- vitamins such as retinol, tocopherol, ascorbic acid, ribofiavine, pyridoxine.
- whole extracts from plants which i.a. contain the above molecules or classes of molecules.
- the active substances are, according to one embodiment of the invention, light protection filters. These can be used as organic sunscreen at room temperature
- Suitable light protection filters are, for example, compounds based on benzophenone, diphenyl cyanoacrylate or
- Amino benzoic acid Concrete examples are (INCI or CTFA designations)
- Benzophenone-3 Benzophenone-4, Benzophenone-2, Benzophenone-6, Benzophenone-9, Benzophenone-1, Benzophenone-11, Etocrylene, Octocrylene, PEG-25 PABA,
- Phenylbenzimidazole sulfonic acid ethylhexyl methoxycinnamate, ethylhexyl dimethyl PABA, 4-methylbenzylidene camphor, butyl methoxydibenzoylmethane, ethylhexyl salicylates, homosalates, and methylene-bis-benzotriazolyl tetramethylbutylphenol (2,2'-methylene-bis- ⁇ 6- (2H-benzoetriazol-2-yl) -4- (1, 1 , 3, 3-tetramethylbutyl) -phenol ⁇ , 2-
- organic sunscreen filters are octyltriazone, avobenzone, octylmethoxycinnamates, octylsalicylates, benzotriazoles and triazines.
- anti-dandruff agents are used as active ingredients, as they are usually present in cosmetic or pharmaceutical formulations.
- An example of this is Piroctone Olamine (1-hydroxy-4-methyl-6- (2,4,4-dimethylpentyl) -2 (1H) -pyridone, preferably in combination with 2-aminoethanol (1: 1)).
- Other suitable agents for the treatment of dander are known in the art.
- ingredients of the emulsions are hydrophilic coated micropigments, electrolytes, glycerol, polyethylene glycol, propylene glycol, barium sulfate, alcohols, waxes, metal soaps, magnesium stearate, vaseline or other ingredients.
- perfumes perfume oils or perfume flavors.
- Suitable cosmetic agents for example polyphenols and compounds derived therefrom.
- Suitable vitamins are retinol, tocopherol, ascorbic acid, riboflavin and pyridoxine.
- active ingredients for example, all oxidation-sensitive active ingredients such as tocopherol come into consideration.
- organic dyes are used as active ingredients or instead of active substances.
- water-in-oil emulsions or oil-in-water emulsions can be prepared by the process according to the invention. These can be used after the emulsifiers described and other ingredients. Furthermore, the preparation of polyol-in-oil emulsions is possible. Any suitable polyols can be used here.
- the proportions of the two main phases can be varied within wide limits. For example, from 5 to 95% by weight, preferably from 10 to 90% by weight, in particular from 20 to 80% by weight, of the respective phases are present, the total amount being 100% by weight.
- the described P / O emulsion can also be emulsified in water or a water-in-oil emulsion. This results in a polyol-in-oil-in-water emulsion (P / O / W emulsion) containing at least one described emulsion and additionally at least one aqueous phase.
- P / O / W emulsion polyol-in-oil-in-water emulsion
- Such multiple emulsions may correspond in structure to the emulsions described in DE-A-43 41 113 and DE-A-43 41114.
- the weight ratio of the individual phases can be varied within wide limits.
- the weight fraction of the P / O emulsion is preferably from 0.01 to 80% by weight, particularly preferably from 0.1 to 70% by weight, in particular from 1 to 30% by weight. %, based on the total P / O / W emulsion.
- the proportion of the P / O emulsion is preferably 0.01 to 60% by weight, particularly preferably 0.1 to 40% by weight, in particular 1 to 30 wt .-%, based on the final P / O / W emulsion.
- the oil content is preferably 1 to 80% by weight, particularly preferably 1 to 30% by weight, based on the O / W emulsion used.
- a W / O emulsion can also be introduced, which leads to a W / O / W emulsion.
- the individual phases of the emulsions may still have conventional ingredients known for the individual phases.
- the individual phases may contain further pharmaceutical or cosmetic active substances which are soluble in these phases.
- the aqueous phase may contain, for example, organic soluble sunscreen, hydrophilically coated micropigment, electrolytes, alcohols, etc.
- any or all of the phases may contain solids which are preferably selected from pigments or micropigments, microspheres, silica gel, and the like.
- the oil phase may contain, for example, organically modified clay minerals, hydrophobically coated (micro) pigments, organic oil-soluble light protection filters, oil-soluble cosmetic agents, waxes, metal soaps such as magnesium stearate, vaseline or mixtures thereof.
- titanium dioxide As (micro) pigments, titanium dioxide, zinc oxide and barium sulfate as well as wollastonite, kaolin, talc, Al 2 O 3 , bismuth oxychloride, micronized polyethylene, Mica, ultramarine, eosin, azo dyes.
- Titanium dioxide or zinc oxide are customary in cosmetics as light protection filters and can be applied particularly smoothly and evenly to the skin by means of the emulsions according to the invention.
- Microspheres or silica gel can be used as carriers for drugs, and waxes can be used, for example, as a base for polishes.
- the water phase may also contain glycerol, polyethylene glycol, propylene glycol,
- aqueous phase water, aqueous solutions or mixtures of water with water-miscible liquids such as glycerol or polyethylene glycol can be used. Further, electrolytes such as sodium chloride may be contained in the aqueous phase. If desired, it is also possible to use viscosity-increasing substances or charge carriers, as described in EP-B-0605 497.
Abstract
Disclosed is a device for on-line process control during the production of emulsions or dispersions. Said device comprises a vessel for accommodating an emulsion or dispersion, a stirring tool located in the vessel for generating a stirring input into the emulsion or dispersion, an apparatus for continuously measuring the stirring input, sensing probes located in the vessel for continuously measuring the temperature and the conductivity of the emulsion or dispersion, and a recording apparatus for continuously recording the stirring input, the temperature, and the conductivity.
Description
Vorrichtung zur In-line-Prozesskontrolle bei der Herstellung von Emulsionen oder Device for in-line process control in the production of emulsions or
Dispersionendispersions
Die Erfindung betrifft eine Vorrichtung zur In-line-Prozesskontrolle bei der Herstellung von Emulsionen oder Dispersionen, die Verwendung einer derartigen Vorrichtung zur Bestimmung geeigneter Prozessparameter für die Herstellung von Emulsionen oder Dispersionen und ein Verfahren zur Bestimmung geeigneter Prozessparameter für die Herstellung von Emulsionen oder Dispersionen.The invention relates to a device for in-line process control in the production of emulsions or dispersions, the use of such a device for determining suitable process parameters for the preparation of emulsions or dispersions and a method for determining suitable process parameters for the preparation of emulsions or dispersions.
Die Herstellung von Emulsionen und Dispersionen erfolgt in der Regel diskontinuierlich in Rührreaktoren. Dabei werden die erforderlichen Mengen der Einsatzstoffe in ein Mischgefäß dosiert und unter hohem Rühreintrag emulgiert oder dispergiert. In der Regel werden dazu Hochleistungsrührer eingesetzt, die die Erzeugung von Kavitationskräften erlauben. Alternativ wird häufig eine Hochdruckhomogenisierung durchgeführt. Eine Kontrolle der hergestellten Emulsion'en und Dispersionen und des Verfahrens erfolgt in der Regel erst am fertigen Produkt der entsprechenden Mischungscharge. Eine kontinuierliche Überprüfung des Herstellungsprozesses ist in der Regel nicht möglich. Da das Produkt jeweils erst nach Fertigstellung der entsprechenden Mischungscharge analysiert werden kann, ist die Einstellung vorteilhafter oder optimaler Prozessparameter zur Herstellung der Emulsionen und Dispersionen schwierig. Eine optimierte Herstellung ist - falls überhaupt - nur aufwendig in zahlreichen Iterationsschritten möglich. Die Bestimmung der gegenseitige Abhängigkeit von Prozessparametern und damit erhaltener Produkte, beispielsweise über den Rühreintrag, die Temperatur und die Art der Zugabe der Inhaltsstoffe, ist nach bekannten Verfahren nicht möglich.The preparation of emulsions and dispersions is usually carried out batchwise in stirred reactors. The required amounts of the starting materials are metered into a mixing vessel and emulsified or dispersed with a high degree of stirring. As a rule, high-performance stirrers are used which allow the generation of cavitation forces. Alternatively, high pressure homogenization is often performed. A control of the emulsions produced and dispersions and of the process usually takes place only on the finished product of the corresponding mixture batch. A continuous review of the manufacturing process is usually not possible. Since the product can be analyzed only after completion of the corresponding batch mixture, the setting of advantageous or optimal process parameters for the preparation of the emulsions and dispersions is difficult. An optimized production is - if any - only consuming possible in numerous iterations. The determination of the interdependence of process parameters and products thus obtained, for example on the Rühreintrag, the temperature and the nature of the addition of the ingredients is not possible by known methods.
Aufgäbe der vorliegenden Erfindung ist die Bereitstellung einer Vorrichtung zur In-Line- Prozesskontrolle bei der Herstellung von Emulsionen oder Dispersionen, sowie eines Verfahrens zur Bestimmung geeigneter Prozessparameter für die Herstellung von Emulsionen oder Dispersionen, wobei die Nachteile der aus dem Stand der Technik bekannten Vorrichtungen und Verfahren vermieden werden sollen.
Die Aufgabe wird erfindungemäß gelöst durch eine Vorrichtung zur In-Line- Prozesskontrolle bei der Herstellung von Emulsionen oder Dispersionen, umfassend ein Gefäß zur Aufnahme einer Emulsion oder Dispersion, ein in dem Gefäß angeordnetes Rührwerkzeug zum Rühreintrag in die Emulsion oder Dispersion, eine Vorrichtung zur kontinuierlichen Messung des Rühreintrags, in dem Gefäß angeordnete Messsonden zur kontinuierlichen Messung der Temperatur und der Leitfähigkeit der Emulsion oder Dispersion sowie eine Aufzeichnungsvorrichtung zur kontinuierlichen Aufzeichnung des Rühreintrags, der Temperatur und der Leitfähigkeit.The object of the present invention is to provide an apparatus for in-line process control in the preparation of emulsions or dispersions, and a method for determining suitable process parameters for the preparation of emulsions or dispersions, wherein the disadvantages of the devices known from the prior art and Procedures should be avoided. The object is achieved according erfindungemäß by an apparatus for in-line process control in the production of emulsions or dispersions, comprising a vessel for receiving an emulsion or dispersion, arranged in the vessel agitator for stirring entry into the emulsion or dispersion, a device for continuous Measuring the stirring entry, measuring probes arranged in the vessel for the continuous measurement of the temperature and the conductivity of the emulsion or dispersion, and a recording device for the continuous recording of the stirring entry, the temperature and the conductivity.
Die Vorrichtung kann zum Beispiel zur diskontinuierlichen Herstellung von Emulsionen und Dispersionen im Labor-, Technikums- oder Produktionsmaßstab dienen.The device can be used, for example, for the discontinuous production of emulsions and dispersions on a laboratory, pilot scale or production scale.
Die Aufgabe wird ferner gelöst durch die Verwendung einer derartigen Vorrichtung zur Bestimmung geeigneter Prozessparameter für die Herstellung von Emulsionen oder Dispersionen.The object is further achieved by the use of such a device for determining suitable process parameters for the preparation of emulsions or dispersions.
Die Aufgabe wird ferner gelöst durch ein Verfahren zur Bestimmung geeigneter Prozessparameter für die Herstellung von Emulsionen oder Dispersionen, bei denen in einer Vorrichtung, wie sie vorstehend beschrieben ist, die Ausgangsstoffe der Emulsionen oder Dispersionen gemeinsam oder getrennt in das Gefäß eingeführt und unter Rühreintrag gemischt werden und der Rühreintrag, die Leitfähigkeit und die Temperatur kontinuierlich gemessen werden und in Abhängigkeit von den erhaltenen Messwerten gegebenenfalls der Rühreintrag und/oder die Temperatur des Gefäßes verändert werden.The object is further achieved by a method for determining suitable process parameters for the preparation of emulsions or dispersions, in which, in a device as described above, the starting materials of the emulsions or dispersions are introduced jointly or separately into the vessel and mixed with stirring and the stirring entry, the conductivity and the temperature are measured continuously and, depending on the measured values obtained, if appropriate, the stirring input and / or the temperature of the vessel are changed.
Die erfindungsgemäße Vorrichtung umfasst zunächst ein Gefäß zur Aufnahme einer Emulsion oder Dispersion oder von Inhaltsstoffen einer Emulsion oder Dispersion sowie zur Aufnahme von Messsonden zur kontinuierlichen Messung der Temperatur und Leitfähigkeit der Emulsion oder Dispersion. Die Messung der Temperatur und Leitfähigkeit kann in einer kombinierten Messsonde erfolgen. Zudem ist das Gefäß so ausgelegt, dass es ein Rührwerkzeug aufnehmen kann. Das Gefäß kann wie bei einem Rührreaktor einseitig (oben) offen sein. Dies ist der übliche Fall. Es ist auch möglich, das Gefäß allseitig geschlossen auszulegen, wobei abgesehen von Zu- und Abführungen sowie Rührerdurchführungen oder Durchführungen für Analytiksensoren das Gefäß geschlossen ist.
Das Rührwerkzeug erlaubt einen mechanischen Rühreintrag in die Emulsion oder Dispersion. Dabei ist das Rührwerkzeug gemäß einer Ausführungsform der Erfindung so ausgelegt, dass es ohne Erzeugung von Kavitationskräften und ohne Hochdruckhomogenisierung arbeitet. In bevorzugten Rührwerkzeugen werden auf einer Rührerachse, die gedreht wird, geeignete Rührelemente angeordnet. Das Rührwerkzeug weist dann mindestens ein von einem Rührmotor über eine gedrehte Rührerachse angetriebenes Rührelement auf. Beim Rührwerkzeug kann es sich um so genannte Rotor/Stator-Systeme handeln, in denen motorbetrieben ein Rotor bewegt wird. Als Stator dient in der Regel das Gehäuse, das mit Einbauten wie Brechern versehen sein kann. Als Rührer kommen beispielsweise Flügelrührer in Betracht, die gegebenenfalls mit Abstreifern versehen sein können. Darüber hinaus können alternativ Kneter und andere geeignete Rührer wie Planetenrührer, Ankerrührer, Balkenrührer, Propeller, Blattrührer, Dissolverscheiben oder Intermig eingesetzt werden. Weitere geeignete Rührerkonfigurationen sind dem Fachmann bekannt.The device according to the invention first comprises a vessel for receiving an emulsion or dispersion or ingredients of an emulsion or dispersion and for receiving measuring probes for the continuous measurement of the temperature and conductivity of the emulsion or dispersion. The measurement of temperature and conductivity can be done in a combined probe. In addition, the vessel is designed so that it can accommodate a stirring tool. The vessel may be open on one side (top) as in a stirred reactor. This is the usual case. It is also possible to design the vessel closed on all sides, with the exception of inlets and outlets and stirrer feedthroughs or feedthroughs for analytical sensors, the vessel is closed. The stirrer allows mechanical stirring into the emulsion or dispersion. In this case, the stirring tool according to an embodiment of the invention is designed so that it works without generating cavitation forces and without high-pressure homogenization. In preferred stirring tools, suitable stirring elements are arranged on a stirrer axis which is rotated. The stirring tool then has at least one stirring element driven by a stirring motor via a rotated agitator axis. The stirring tool may be so-called rotor / stator systems in which a rotor is moved by motor-driven operation. The stator is usually the housing, which may be provided with internals such as crushers. Suitable stirrers are, for example, paddle stirrers, which may optionally be provided with scrapers. In addition, kneaders and other suitable stirrers such as planetary stirrers, anchor stirrers, bar stirrers, propellers, blade stirrers, dissolver disks or Intermig can be used as an alternative. Other suitable stirrer configurations are known to those skilled in the art.
Das Rührwerkzeug wird vorzugsweise so betrieben, dass der Rühreintrag in die Emulsion oder Dispersion ohne Erzeugung von Kavitationskräften und ohne Hochdruckhomogenisierung erfolgt.The stirring tool is preferably operated in such a way that the stirring entry into the emulsion or dispersion takes place without generation of cavitation forces and without high-pressure homogenization.
Ein Homogenisator kann zusätzlich im (zum Beispiel in Bodennähe) oder am Rührgefäß vorgesehen sein. Das Gefäß kann auch einen Umlauf aufweisen, in dem zum Beispiel ein Homogenisator vorgesehen werden kann.A homogenizer may additionally be provided in (for example near the bottom) or on the mixing vessel. The vessel can also have a circulation in which, for example, a homogenizer can be provided.
Im Gefäß können zudem gegebenenfalls Mahlwerkzeuge wie Mahlperlen oder -kugeln vorliegen. Geeignete Mahlwerkzeuge sind dem Fachmann bekannt.If necessary, grinding tools such as grinding beads or balls may also be present in the vessel. Suitable grinding tools are known in the art.
Das Gefäß (Mischgefäß) kann jede geeignete Geometrie aufweisen, so lange es eine geeignete Durchmischung der fließfähigen Stoffe oder Stoffgemische bzw. der Phasen der herzustellenden Emulsionen und Dispersionen erlaubt. Geeignete Geometrien sind dem Fachmann bekannt. Vorzugsweise weist das Mischgefäß innen eine im Wesentlichen zylindrische Form auf, wobei die Achse des Rührwerkzeugs in der Zylinderachse liegt. Die Anordnung der Messsonde oder Messsonden kann direkt im zylindrischen Raum des Gefäßes vorgesehen sein. Es ist auch möglich, zwei zylindrische Gefäße vorzusehen, die zueinander parallel und beabstandet sind und die am unteren Ende so miteinander in Verbindung stehen, dass durch einen Rühreintrag eine Vermischung in beiden
zylindrischen Gefäßen erfolgen kann. Eine derartige Ausführungsform ist in den beigefügten Figuren 1 bis 3 beschrieben.The vessel (mixing vessel) can have any suitable geometry, as long as it allows a suitable mixing of the flowable substances or mixtures or the phases of the emulsions and dispersions to be prepared. Suitable geometries are known to the person skilled in the art. The mixing vessel preferably has an essentially cylindrical shape on the inside, the axis of the stirring tool lying in the cylinder axis. The arrangement of the measuring probe or probes can be provided directly in the cylindrical space of the vessel. It is also possible to provide two cylindrical vessels which are parallel and spaced from each other and which communicate with each other at the lower end so as to mix in both of them by means of stirring can be made cylindrical vessels. Such an embodiment is described in the attached Figures 1 to 3.
In der Zeichnung zeigen die Figuren 1 und 2 zueinander senkrechte Querschnittsdarstellungen durch das erfindungsgemäße Gefäß. Figur 3 zeigt eine Draufsicht auf das Gefäß. Figur 4 zeigt den schematischen Aufbau des isolierten Rührschafts. Figur 5 zeigt den schematischen Aufbau der erfindungsgemäßen Vorrichtung. Die Figuren 6 bis 10 zeigen Auftragungen der Leitfähigkeit gegen die Messzeit bzw. Temperatur. Die Figuren werden nachstehend jeweils näher erläutert.In the drawing, Figures 1 and 2 show mutually perpendicular cross-sectional views through the vessel according to the invention. FIG. 3 shows a plan view of the vessel. Figure 4 shows the schematic structure of the isolated stirrer. FIG. 5 shows the schematic structure of the device according to the invention. FIGS. 6 to 10 show plots of the conductivity versus the measuring time or temperature. The figures will be explained in more detail below.
Figur 1 und Figur 2 zeigen Querschnitte durch das in der erfindungsgemäßen Vorrichtung vorgesehene Gefäß. Das Gefäß weist einen Mantel zur Temperierung auf, durch den eine Temperierflüssigkeit geführt werden kann. In Figur 1 sind links oben und rechts unten die Zu- bzw. Abführung für das Temperiermittel, insbesondere Kühlmittel oder Heizmittel, gezeigt. Die entsprechenden Zu- und Abführungen sind auch in Figur 2 unten und oben als (gestrichelte) Kreise gezeigt, während sie in Figur 3 links und rechts des Gefäßes erkennbar sind. Wie aus den Figuren 1 bis 3 hervorgeht, sind im Kühl/Heizmantel zwei zylindrische Aussparungen mit unterschiedlichem Durchmesser vorgesehen, die im unteren Bereich miteinander verbunden sind. Dies geht insbesondere aus Figur 2 hervor. In Figur 2 sind links die zylindrische Öffnung mit geringerem Durchmesser und rechts die zylindrische Öffnung mit größerem Durchmesser zu sehen, die im unteren Bereich miteinander verbunden sind. Die linke Öffnung nimmt die Messsonde für Temperatur und Leitfähigkeit auf, während die rechte Öffnung das Rührwerkzeug aufiiimmt. Sowohl die Messsonde als auch das Rührwerkzeug werden von oben eingeführt. Die entsprechenden Öffnungen sind in Figur 3 von oben gezeigt. Beim Betrieb wird durch das Rührwerkzeug eine Durchmischung der Emulsionen/Dispersionen erreicht, so dass auch in der linken zylindrischen Öffnung die gemischte Emulsion/Dispersion an der Messsonde vorbei strömt.FIG. 1 and FIG. 2 show cross sections through the vessel provided in the device according to the invention. The vessel has a jacket for temperature control, through which a temperature control liquid can be passed. In Figure 1, the supply and discharge for the temperature control, in particular coolant or heating means are shown left top and bottom right. The corresponding inlets and outlets are also shown in Figure 2 below and above as (dashed) circles, while they are recognizable in Figure 3 left and right of the vessel. As is apparent from Figures 1 to 3, two cylindrical recesses of different diameters are provided in the cooling / heating jacket, which are interconnected in the lower region. This is apparent in particular from FIG. In FIG. 2, to the left, the smaller diameter cylindrical aperture and, to the right, the larger diameter cylindrical aperture, which are interconnected in the lower region, are shown. The left port accepts the temperature and conductivity probe, while the right port picks up the agitator. Both the probe and the stirring tool are inserted from above. The corresponding openings are shown in Figure 3 from above. During operation, mixing of the emulsions / dispersions is achieved by the stirring tool, so that the mixed emulsion / dispersion also flows past the measuring probe in the left-hand cylindrical opening.
Das erfindungsgemäß eingesetzte (Misch)Gefäß kann in der Größe nach den jeweiligen praktischen Erfordernissen gewählt werden. Ln Labormaßstab beträgt das Innenvolumen (Frei volumen) des (Misch)Gefaßes vorzugsweise 50 ml bis 10 1, besonders bevorzugt 100 ml bis 5 1, insbesondere 300 bis 1000 ml. Im Technikumsmaßstab beträgt das Innenvolumen vorzugsweise 5 bis 100 ml, besonders bevorzugt 10 bis 50 1. Im Großtechnischen oder Produktions-Maßstab beträgt das Volumen bzw.
Aufhahmevermögen vorzugsweise mehr als 20 Tonnen, beispielsweise mehr als 50 Tonnen.The (mixed) vessel used according to the invention can be selected in size according to the respective practical requirements. On the laboratory scale, the internal volume (free volume) of the (mixed) vessel is preferably 50 ml to 10 l, more preferably 100 ml to 5 l, in particular 300 to 1000 ml. In the pilot plant scale, the internal volume is preferably 5 to 100 ml, more preferably 10 to 50 1. On a large-scale or production scale, the volume or Take up capacity preferably more than 20 tons, for example more than 50 tons.
Im Labormaßstab können beispielsweise (Misch)Gefaße eingesetzt werden, in denen die Höhe der zylinderförmigen Aussparungen etwa 13 cm beträgt. Die Innendurchmesser derOn a laboratory scale, for example (mixed) vessels can be used, in which the height of the cylindrical recesses is about 13 cm. The inner diameter of the
Aussparungen betragen beispielsweise 15 und 48 mm. Das gesamte Gefäß einschließlichRecesses are for example 15 and 48 mm. Including the entire vessel
Mantel weist beispielsweise einen Außendurchmesser von 92 mm auf. Bei der gezeigten insgesamt zylinderförmigen Ausführung des Gefäßes beträgt der äußere Durchmesser einschließlich Mantel vorzugsweise 50 bis 350 mm. Der Durchmesser der größeren zylindrischen Öffnung beträgt vorzugsweise 25 bis 300 mm.For example, the jacket has an outer diameter of 92 mm. In the overall cylindrical embodiment of the vessel shown, the outer diameter including shell is preferably 50 to 350 mm. The diameter of the larger cylindrical opening is preferably 25 to 300 mm.
In den Figuren 1 bis 3 ist ein Temperiermantel, der von einem Temperiermedium durchströmt wird, gezeigt. Es können jedoch auch andere geeignete Vorrichtungen zum Temperieren des Gefäßes vorgesehen werden.FIGS. 1 to 3 show a temperature control jacket through which a temperature control medium flows. However, other suitable devices for controlling the temperature of the vessel may be provided.
Es ist auch möglich, zum Beispiel kontinuierlich, einen Teil des Inhalts eines Mischgefaßes im Produktionsmaßstab zu entnehmen und einer erfindungsgemäßen Vorrichtung zuzuführen. Dabei kann beispielsweise der Rühreintrag in beiden Gefäßen einander angepasst werden. Es ist auch möglich, in der erfindungsgemäßen Vorrichtung vorteilhafte Prozeßparameter zu ermitteln und diese dann auf die Produktion zeitnah zu übertragen.It is also possible, for example continuously, to take part of the contents of a mixing vessel on a production scale and feed it to a device according to the invention. In this case, for example, the stirring entry in both vessels can be adapted to each other. It is also possible to determine advantageous process parameters in the device according to the invention and then to transmit them to the production in a timely manner.
Die erfindungsgemäße Vorrichtung dient insbesondere zur diskontinuierlichen Herstellung von Emulsionen oder Dispersionen. Dabei wird das gezeigte Gefäß mit den Inhaltsstoffen der Emulsionen bzw. Dispersionen durch die oben angeordneten Öffnungen beschickt, und die fertige Dispersion oder Emulsion wird ebenfalls durch diese Öffnung entnommen. Andere Geometrien des Gefäßes, der Beschickung und Entnahme sind dem Fachmann bekannt. Die Vorrichtung zur In-line-Prozesskontrolle kann auch in bereits bestehende übliche Rührgefäße im Technikums- oder Produktionsmaßstab, zum Beispiel nachträglich, integriert werden.The device according to the invention is used in particular for the discontinuous production of emulsions or dispersions. In this case, the container shown is charged with the ingredients of the emulsions or dispersions through the openings arranged above, and the finished dispersion or emulsion is also removed through this opening. Other geometries of the vessel, the loading and unloading are known in the art. The device for in-line process control can also be integrated into already existing conventional stirring vessels in pilot plant or production scale, for example subsequently.
Sofern der Rühreintrag über ein von einem Rührmotor über eine gedrehte Rührerachse angetriebenes Rührelement erfolgt, weist die Rührerachse in ihrem Verlauf vorzugsweise eine elektrische Isolierung derart auf, dass Rührelement und Rührmotor voneinander elektrisch isoliert sind. Eine beispielhafte Ausführungsform dieser Isolierung ist in Figur 4 schematisch gezeigt. R bedeutet dabei die Rührerachse, S einen auf die Rührerachse
aufgezogenen Schrumpfschlauch aus nicht leitendem Kunststoffinaterial, und M eine auf den Schrumpfschlauch aufgeschobene Metallhülse. Durch den zwischen der Rührerachse und der Metallhülse liegenden Schrumpfschlauch wird die elektrische Isolierung der Rührerachse bewirkt. Die Isolierung verhindert mögliche Interferenzen mit der Leitfähigkeits/Temperatur-Messung.If the stirring is carried out via a stirring element driven by a stirring motor via a rotated agitator axis, the stirrer axis preferably has an electrical insulation in its course in such a way that the stirring element and the stirring motor are electrically insulated from one another. An exemplary embodiment of this insulation is shown schematically in FIG. R stands for the stirrer axis, S stands for the stirrer axis mounted shrink tubing made of non-conductive plastic material, and M is a pushed onto the shrink tubing metal sleeve. By lying between the stirrer axis and the metal sleeve shrink tubing electrical insulation of the stirrer axis is effected. The insulation prevents possible interference with the conductivity / temperature measurement.
Figur 5 zeigt den schematischen Aufbau der gesamten Vorrichtung an einem Beispiel. Das Rührwerkzeug Ru weist ein Magnetband Ma auf, das wiederum als Signalgeber für einen Drehzahlsensor Dr dient. Vom Rührwerkzeug ragt die Rührerachse in das Gefäß. Ferner ragt eine Messsonde zur Messung der Temperatur und Leitfähigkeit Le ebenfalls in das Gefäß. Sowohl der Drehzahlsensor als auch die Messsonde sind mit einem Steuer- und Aufzeichnungsgerät St verbunden, das wiederum von einem Rechner Re angesteuert wird, und das Daten an den Rechner überträgt. Über einen Monitor Mo kann die Steuerung der Temperatur und Drehzahl sowie die Messung der Parameter überprüft werden. Nicht gezeigt ist eine Eingabeeinheit, beispielsweise eine Tastatur, mit der der Rechner und das Steuergerät angesteuert werden können. Üblicherweise werden auch Ausgabemedien für die Informationen vorgesehen. Sowohl die Ansteuerung des Rührmotors und gegebenenfalls von Pumpen oder Dosiereinrichtungen für die Inhaltsstoffe der Emulsionen oder Dispersionen als auch die Messwertaufnahme können über einen zentralen Rechner angesteuert werden. Die Auswertung der erhaltenen Messwerte (Parameter) erfolgt vorzugsweise ebenfalls über einen zentralen Rechner.Figure 5 shows the schematic structure of the entire device by way of example. The stirring tool Ru has a magnetic belt Ma, which in turn serves as a signal generator for a rotational speed sensor Dr. From the stirring tool, the stirrer axis protrudes into the vessel. Furthermore, a measuring probe for measuring the temperature and conductivity Le also protrudes into the vessel. Both the speed sensor and the measuring probe are connected to a control and recording device St, which in turn is controlled by a computer Re, and transmits the data to the computer. A monitor Mo can be used to check the control of the temperature and speed as well as the measurement of the parameters. Not shown is an input unit, such as a keyboard, with which the computer and the control unit can be controlled. Usually also output media are provided for the information. Both the control of the stirring motor and optionally of pumps or metering devices for the ingredients of the emulsions or dispersions and the measured value recording can be controlled via a central computer. The evaluation of the obtained measured values (parameters) preferably also takes place via a central computer.
Die kontinuierliche Aufzeichnung des Rühreintrags, der Temperatur und der Leitfähigkeit kann mit Hilfe des Rechners, jedoch auch über andere geeignete Medien wie Drucker oder Plotter erfolgen. Dabei sind der Rühreintrag und gegebenenfalls die Temperierung des Gefäßes rechnergesteuert, und die kontinuierliche Aufzeichnung und gegebenenfalls Auswertung des Rühreintrags, der Temperatur und der Leitfähigkeit erfolgt ebenfalls rechnergestützt.The continuous recording of the stirring, the temperature and the conductivity can be done with the help of the computer, but also via other suitable media such as printers or plotters. In this case, the stirring entry and optionally the temperature of the vessel are computer controlled, and the continuous recording and optionally evaluation of the Rühreintrags, the temperature and the conductivity is also computerized.
Mit der erfindungsgemäßen Vorrichtung können fertig formulierte Emulsionen und Dispersionen auf ihr Temperatur- und Scherverhalten hin untersucht werden. Ferner können bei der Herstellung der Emulsionen und Dispersionen kritische Parameter bestimmt und optimiert werden. Bei der Herstellung von Dispersionen ist die Pigmentzugabe in der Regel kritisch. Mit der erfindungsgemäßen Vorrichtung kann in einfacher Weise ermittelt werden, wie viel Pigment in eine Emulsion eingetragen werden kann, und wann die Pigmentzugabe idealerweise erfolgt. Weiterhin kann die Ausbildung
einer LC-Phase in einer Emulsion zeitaufgelöst bestimmt werden. Durch unterschiedliche Rührergeschwindigkeiten können Scaling-up-Parameter bei der Herstellung bestimmt werden. Die Ausbildung von LC-Gelnetzwerken kann über die Leitfähigkeit bei unterschiedlichen Temperaturen bestimmt werden. Ebenso kann der Einfluss niedriger oder hoher Drehzahlen hierbei beobachtet werden.With the device according to the invention, ready-formulated emulsions and dispersions can be examined for their temperature and shear behavior. Furthermore, critical parameters can be determined and optimized in the preparation of the emulsions and dispersions. In the preparation of dispersions, the pigment addition is usually critical. With the device according to the invention it can be determined in a simple manner how much pigment can be introduced into an emulsion and when the pigment addition ideally takes place. Furthermore, the training a LC phase in an emulsion are determined time-resolved. Different stirrer speeds can be used to determine scaling-up parameters during production. The formation of LC gel networks can be determined by the conductivity at different temperatures. Similarly, the influence of low or high speeds can be observed here.
Bei der Herstellung von Emulsionen und Dispersionen im Technikums- oder Produktionsmaßstab kann der Fortgang der Vermischung bzw. Emulgierung oder Dispergierung in jeder Verfahrensstufe und zu jedem Verfahrenszeitpunkt ohne Zeitverzögerung in Echtzeit, d. h. in-line, und im Rührkessel selbst, analysiert werden, so dass geeignete Maßnahmen wie Anpassung des Rühreintrags, der Temperatur, oder Zudosierung (Zeitpunkt, Geschwindigkeit, Menge) von Emulsions- oder Dispersionskomponenten, angesteuert werden können, um die Herstellung der Emulsionen oder Dispersionen zu optimieren.In the preparation of pilot scale or production scale emulsions and dispersions, the progress of blending or emulsification or dispersion at any stage of the process and at any stage in the process can be accomplished in real time with no time delay, ie. H. be analyzed in-line, and in the stirred tank itself, so that appropriate measures such as adjustment of the stirring, the temperature, or addition (time, speed, amount) of emulsion or dispersion components, can be controlled to the production of emulsions or dispersions to optimize.
Insgesamt erlaubt die kontinuierliche Bestimmung eines oder mehrerer der genannten Parameter eine kontinuierliche Prozesskontrolle und eine kontinuierliche Kontrolle der Zusammensetzung der Emulsion bzw. Dispersion. Die Qualitätssicherung bei der Herstellung wird damit erheblich verbessert bzw. vereinfacht. Dies ist insbesondere bei pharmazeutischen Produkten von hoher Wichtigkeit.Overall, the continuous determination of one or more of the mentioned parameters allows a continuous process control and a continuous control of the composition of the emulsion or dispersion. The quality assurance in the production is thus considerably improved or simplified. This is particularly important in pharmaceutical products of high importance.
Die erfindungsgemäße Vorrichtung erlaubt zum Beispiel die ideale In-Line- Prozesskontrolle für die Herstellung von Öl-in-Wasser Emulsionen oder wasserbasierenden Dispersionen. Während der Herstellung werden laufend wichtige Parameter wie Umfangsgeschwindigkeit des Rührers, Temperatur der Emulsion/Dispersion und Leitfähigkeit der Emulsion/Dispersion automatisch aufgezeichnet. Die Leitfähigkeitsdaten, die während des Emulgierprozesses ermittelt werden, erlauben eine sehr gute Interpretation der Emulsionsstruktur in Abhängigkeit der Temperatur und Rührintensität. Die Leitfähigkeit einer Emulsion/Dispersion steht in direktem Zusammenhang zu deren Dispersionsgrad, Viskosität und Struktur.The device according to the invention allows, for example, the ideal in-line process control for the preparation of oil-in-water emulsions or water-based dispersions. During production, important parameters such as peripheral speed of the stirrer, temperature of the emulsion / dispersion and conductivity of the emulsion / dispersion are continuously recorded automatically. The conductivity data, which are determined during the emulsification process, allow a very good interpretation of the emulsion structure as a function of temperature and stirring intensity. The conductivity of an emulsion / dispersion is directly related to its degree of dispersion, viscosity and structure.
Bestimmung des Dispersionsgrades durch In-Line-Leitfähigkeitsmessungen von DispersionenDetermination of the degree of dispersion by in-line conductivity measurements of dispersions
Mit steigendem Dispersionsgrad nimmt die Leitfähigkeit einer Emulsion/Dispersion bzw. die Ionenbeweglichkeit in der wässrigen Phase ab, da mit steigenden Dispersionsgrad die
Viskosität nach der Einstein' sehen Beziehung zunimmt. Es herrscht in einer Emulsion/Dispersion also ein Gleichgewicht zwischen Viskosität und Dispersionsgrad.As the degree of dispersion increases, the conductivity of an emulsion / dispersion or the mobility of the ions in the aqueous phase decreases, since with increasing degree of dispersion the Viscosity after Einstein's relationship is increasing. There is thus an equilibrium between viscosity and degree of dispersion in an emulsion / dispersion.
Mischt man zum Beispiel einer O/W-Emulsion ein Pigment zu, so nimmt die Leitfähigkeit nach Zugabe dieses Pigments ab. Ist die Rührgeschwindigkeit während der Pigmentzugabe genügend hoch, so stellt sich fast unmittelbar nach Pigmentzugabe ein Gleichgewicht ein. Mit Zunehmen der Pigmentzugabe dauert bei gleicher Rührleistung die Pigmentverteilung länger. Stellt sich das Gleichgewicht nur sehr langsam ein, ist es ratsam, die Umfangsgeschwindigkeit zu erhöhen. Wie aus Figur 6 ersichtlich, spiegelt die In-Line Messung der erfindungsgemäßen Vorrichtung diesen Vorgang sehr gut wieder. Figur 6 zeigt eine Pigmentzugabe zu einer Emulsion. An den mit den Pfeilen markierten Stellen wurden jeweils 2 g Pigment zur Emulsion unter Rühren hinzugegeben. Es wurde die Leitfähigkeit in Abhängigkeit von der Messzeit bestimmt. Die Kurve zeigt an, nach welcher Zeit ein Gleichgewicht erreicht wird (Steigung der Kurve nähert sich Null). Es ist ersichtlich, dass sich nach der letzten Pigmentzugabe die Leitfähigkeit kontinuierlich weiter vermindert. Dies bedeutet, dass vor der letzten Pigmentzugabe die maximale im Gleichgewicht verträgliche Pigmentmenge bei der gewählten Rührergeschwindigkeit zugegeben wurde. Damit erlaubt die vorliegende Erfindung die indirekte Messung der Pigmentdispergierung und die Messung der Menge an Pigment, die in einer Emulsion dispergiert werden kann.If, for example, a pigment is added to an O / W emulsion, the conductivity decreases after the addition of this pigment. If the stirring speed during the pigment addition is sufficiently high, an equilibrium sets in almost immediately after pigment addition. As the pigment addition increases, the pigment distribution lasts longer with the same stirring power. If the balance is very slow, it is advisable to increase the peripheral speed. As can be seen from FIG. 6, the in-line measurement of the device according to the invention reflects this process very well. FIG. 6 shows a pigment addition to an emulsion. At the points marked with the arrows, 2 g of pigment were added to the emulsion with stirring. The conductivity was determined as a function of the measuring time. The curve indicates after which time an equilibrium is reached (slope of the curve approaches zero). It can be seen that, after the last addition of pigment, the conductivity continues to decrease continuously. This means that before the last pigment addition, the maximum amount of pigment compatible in equilibrium was added at the chosen stirrer speed. Thus, the present invention allows the indirect measurement of pigment dispersion and the measurement of the amount of pigment that can be dispersed in an emulsion.
Emulsionenemulsions
In Emulsionen muss die Leitfähigkeit jedoch mit zunehmendem Dispersionsgrad nicht zwingend abfallen. Hier kann sie auch mit steigendem Dispersionsgrad zunehmen. DiesesIn emulsions, however, the conductivity does not necessarily decrease with increasing degree of dispersion. Here it can also increase with increasing degree of dispersion. This
Phänomen tritt insbesondere dann auf, wenn ionogene Emulgatoren verwendet werden.Phenomenon particularly occurs when ionogenic emulsifiers are used.
Mit zunehmendem Dispersionsgrad der Öltröpfchen entsteht eine immer größereAs the degree of dispersion of the oil droplets increases, so does an ever larger one
Grenzfläche, die von Emulgatoren belegt wird. Über die Dissoziation des Gegenions desInterface occupied by emulsifiers. About the dissociation of the counterion of
Emulgators steigt die Ionenkonzentration in der Wasserphase und somit die Leitfähigkeit der Emulsion an. Ein typisches Beispiel, wie die Leitfähigkeit einer O/W Emulsion, die durch ionogene Emulgatoren stabilisiert ist, steigt, zeigt Figur 7. In Figur 7 ist dieEmulsifier increases the ion concentration in the water phase and thus the conductivity of the emulsion. A typical example of how the conductivity of an O / W emulsion stabilized by ionic emulsifiers increases is shown in FIG
Leitfähigkeit in Abhängigkeit von der Messzeit aufgetragen. Die einzelnen Pfeile bezeichnen unterschiedliche Zugaben bei der Herstellung einer Emulsion. Zunächst wird von demineralisiertem Wasser ausgegangen. An der ersten mit einem Pfeil markierten Stelle wurde Xanthan Gum zugegeben. An der zweiten mit einem Pfeil markierten Stelle wurde die Ölphase zugegeben. An der dritten mit einem Pfeil markierten Stelle wurde mit
dem Abkühlen der Emulsion begonnen, wodurch sich eine LC-Phase ausbildet. Anhand der Leitfähigkeit kann die Bildung der LC-Phase gut verfolgt werden.Conductivity applied as a function of the measuring time. The individual arrows indicate different additions in the preparation of an emulsion. First, it is assumed that demineralized water. Xanthan gum was added at the first point marked with an arrow. At the second point marked with an arrow, the oil phase was added. At the third point marked with an arrow was with the emulsion is cooled to form an LC phase. Based on the conductivity, the formation of the LC phase can be followed well.
Erfassung von StrukturbildungenDetection of structure formations
Öl-in- Wasser Emulsionen werden häufig über liquid kristalline Gelnetzwerke stabilisiert. Diese bilden sich je nach Schmelzpunkt der Mischemulgatoren im Temperaturbereich unterhalb von 60 °C aus.Oil-in-water emulsions are often stabilized by liquid crystalline gel networks. These are formed depending on the melting point of the mixing emulsifiers in the temperature range below 60 ° C.
Ab welcher Temperatur die Bildung einsetzt und bei welcher Temperatur sie abgeschlossen ist, kann sehr gut mit der erfindungsgemäßen Vorrichtung verfolgt werden.From which temperature the formation begins and at which temperature it is completed, can be followed very well with the device according to the invention.
Somit ist es möglich, die kritische Temperatur zu erfassen, bei der eine optimale Homogenisation erfolgen soll oder zum Beispiel Konservierungsstoffe vorzugsweise eingearbeitet werden. Figur 8 zeigt die Bestimmung der kritischen Gelnetzwerk- Temperatur beim Abkühlen. Es ist die Leitfähigkeit in Abhängigkeit von der Temperatur aufgetragen. Bei niedriger Temperatur liegt ein LC-Gelnetzwerk vor. Vorzugsweise werden bei diesen Temperaturen, bei denen ein LC-Gelnetzwerk vorliegt, Konservierungsstoffe eingetragen, da geringere Mengen für eine gute Wirksamkeit erforderlich sind. Bei der Temperatur, bei der die Leitfähigkeit zunimmt, kann durch Nachhomogenisieren die Teilchengröße wieder vermindert werden. Über die Übergangstemperatur zum LC-Gelnetzwerk sind auch Aussagen über die Wasserfestigkeit von beispielsweise Lichtschutzmitteln möglich. Ein Übergang bei etwa 30 °C bedeutet dabei eine nicht wasserfeste Zusammensetzung.Thus, it is possible to detect the critical temperature at which optimal homogenization is to take place or, for example, preservatives are preferably incorporated. FIG. 8 shows the determination of the critical gel network temperature during cooling. It is the conductivity as a function of the temperature applied. At low temperature there is a LC gel network. Preservatives are preferably added at these temperatures in which an LC gel network is present since smaller amounts are required for good efficacy. At the temperature at which the conductivity increases, the particle size can be reduced again by post-homogenization. About the transition temperature to the LC gel network also statements about the water resistance of, for example, sunscreen agents are possible. A transition at about 30 ° C means a non-waterproof composition.
Figur 9 zeigt den Einfluss der Rührgeschwindigkeit auf die benötigte Emulgierzeit. Es ist jeweils die Leitfähigkeit in Abhängigkeit der Messzeit aufgetragen. Für eine Emulsion, die mit einer Rührergeschwindigkeit von 3,15 m/s hergestellt wurde, bildet sich eine stabile Emulsion bereits nach etwa 2000 s, während bei einer Rührergeschwindigkeit von 1,44 m/s mehr als 3000 s benötigt werden. Damit lassen sich mit der erfindungsgemäßen Vorrichtung optimale Rührergeschwindigkeiten und damit Scaling-up-Parameter bestimmen.FIG. 9 shows the influence of the stirring speed on the required emulsification time. In each case the conductivity is plotted as a function of the measuring time. For an emulsion which was prepared with a stirrer speed of 3.15 m / s, a stable emulsion forms after about 2000 s, while at a stirrer speed of 1.44 m / s more than 3000 s are required. Thus, with the device according to the invention, optimum stirrer speeds and thus scaling-up parameters can be determined.
Figur 10 zeigt das Verhalten der LC-Gelnetzwerkbildung bei unterschiedlicher Herstellungstemperatur. Es ist die Leitfähigkeit in Abhängigkeit von der Temperatur aufgetragen. Ein erstes LC-Gelnetzwerk wurde bei 80 0C hergestellt, ein zweites LC-
Gelnetzwerk bei 65 0C. Für das bei höherer Temperatur hergestellte Gelnetzwerk ergibt sich bei niedrigeren Temperaturen eine niedrigere Leitfähigkeit, wie in Figur 10 dargestellt.FIG. 10 shows the behavior of the LC gel network formation at different production temperatures. It is the conductivity as a function of the temperature applied. A first LC-gel network was made at 80 0 C, a second LC Gel network at 65 0 C. For the gel network produced at a higher temperature results in lower temperatures, a lower conductivity, as shown in Figure 10.
Die vorstehenden Beispiele zeigen, dass mit der erfindungsgemäßen Vorrichtung und dem erfindungsgemäßen Verfahren eine Vielzahl von praxisrelevanten Prozessparametern für die Herstellung von Emulsionen und Dispersionen aufgefunden werden können. Kritische Parameter können in einfacher Weise bestimmt werden. Durch Variation des Rühreintrags kann die Emulsionsqualität in Abhängigkeit der Rührergeschwindigkeit beurteilt werden. Die Messdaten, Rührergeschwindigkeit, Leitfähigkeit und Temperatur werden direkt im (Misch)Gefäß bestimmt.The above examples show that with the device according to the invention and the method according to the invention a multiplicity of practically relevant process parameters for the production of emulsions and dispersions can be found. Critical parameters can be easily determined. By varying the stirring entry, the emulsion quality can be assessed as a function of the stirrer speed. The measured data, stirrer speed, conductivity and temperature are determined directly in the (mixing) vessel.
Erfindungsgemäß kann die Herstellung von Emulsionen und Dispersionen untersucht werden, die unterschiedlichste Volumenanteile der dispersen Phase haben. Üblicherweise entspricht die Abhängigkeit der Viskosität einer Emulsion bzw. Dispersion vom Volumenanteil der dispersen Phase einer Exponentialfunktion. Der wichtige viskoelastische Bereich, in dem erfindungsgemäß gearbeitet werden kann, ist der Bereich, bei dem sich die Viskosität mit zunehmendem Volumenanteil der dispersen Phase sehr stark erhöht. Bei einer zweiphasigen Emulsion wird das Gewichtsverhältnis der Phasen vorzugsweise in einem Bereich von 1:15 bis 15:1, bevorzugt 1:5 bis 5:1, vorzugsweise 1:2 bis 2:1, insbesondere 1 :1,5 bis 1,5:1 gewählt. Insbesondere bei Öl/Wasser-Emulsionen (OAV), Wasser/Öl-Emulsionen (W/O) und Polyol/Öl-Emulsionen (P/O) liegen die Gewichtsanteile der entsprechenden Phasen vorzugsweise in diesem Bereich.According to the invention, it is possible to investigate the production of emulsions and dispersions which have very different volume fractions of the disperse phase. The dependence of the viscosity of an emulsion or dispersion on the volume fraction of the disperse phase usually corresponds to an exponential function. The important viscoelastic region in which it is possible to work according to the invention is the region in which the viscosity increases very sharply with increasing volume fraction of the disperse phase. In a biphasic emulsion, the weight ratio of the phases is preferably in a range of 1:15 to 15: 1, preferably 1: 5 to 5: 1, preferably 1: 2 to 2: 1, especially 1: 1.5 to 1.5 : 1 chosen. Especially in the case of oil / water emulsions (OAV), water / oil emulsions (W / O) and polyol / oil emulsions (P / O), the proportions by weight of the corresponding phases are preferably in this range.
Es kann bei der Herstellung der Emulsionen und Dispersionen auch zunächst hochviskos und nachfolgend durch weitere Verdünnung niederviskos gearbeitet werden. Die Einstellung einer feinteiligen Emulsion bzw. Dispersion wird dabei im hochviskosen Bereich erreicht, während die Verdünnung auf die endgültige Konzentration anschließend erfolgt. Für eine Beschreibung der Viskoelastizität kann auf Römpp, Chemielexikon, 9. Auflage, Stichwort „Viskoelastizität" verwiesen werden.In the preparation of the emulsions and dispersions, it is also possible initially to work with high viscosity and subsequently by low-viscosity dilution. The setting of a finely divided emulsion or dispersion is achieved in the high-viscosity range, while the dilution to the final concentration then takes place. For a description of the viscoelasticity, reference may be made to Römpp, Chemielexikon, 9th edition, keyword "viscoelasticity".
Durch Einhalten des angegebenen Mengenverhältnisses der beiden Phasen kann selbst mit dem Eintrag geringer Scherenergien eine sehr starke Mischwirkung erreicht werden. Ohne an eine Theorie gebunden zu sein kann die beim Vermischen der Phasen erhaltene Microemulsion als ein System zweier interpenetrierender Netzwerke verstanden werden, so dass die Microemulsion einphasiges Verhalten zeigt.
Über die Leitfähigkeit sind Aussagen über das Phasenvolumenverhältnis möglich. Durch Messung der Leitfähigkeit lassen sich deshalb Veränderungen in der Emulsionszusammensetzung bzw. in den Phasenvolumina leicht bestimmen. Die Prozesskontrolle wird in-line, zum Beispiel im Produktionsmaßstab, beispielsweise bis zum Tonnenmaßstab im Bereich von zum Beispiel 1 bis 20 Tonnen Emulsion oder Dispersion, durchgeführt, d. h. kontinuierlich während des Herstellungsverfahrens. Dies erlaubt es, auf Abweichungen der Zusammensetzungen der Emulsionen oder Dispersionen sofort zu reagieren, so dass letztendlich identische Chargen erhalten werden können. Beispielsweise kann durch Steuerung des Rühreintrags die Herstellung der Emulsionen und Dispersionen gesteuert werden. Die Prozesskontrolle erfolgt dabei durch die beschriebenen Messungen zum Beispiel direkt im Rührreaktor bzw. Mischgefäß, so dass eine Produktions- oder Qualitätskontrolle für zum Beispiel ein Handelsprodukt resultiert.By maintaining the specified ratio of the two phases, a very strong mixing effect can be achieved even with the entry of low shear energies. Without wishing to be bound by theory, the microemulsion obtained by mixing the phases can be understood as a system of two interpenetrating networks, so that the microemulsion exhibits single-phase behavior. About the conductivity statements about the phase volume ratio are possible. By measuring the conductivity, it is therefore easy to determine changes in the emulsion composition or in the phase volumes. The process control is carried out in-line, for example on a production scale, for example up to the ton scale in the range of, for example, 1 to 20 tons of emulsion or dispersion, ie continuously during the manufacturing process. This makes it possible to react immediately to deviations of the compositions of the emulsions or dispersions, so that ultimately identical batches can be obtained. For example, by controlling the stirring, the production of the emulsions and dispersions can be controlled. The process control is carried out by the described measurements, for example, directly in the stirred reactor or mixing vessel, so that a production or quality control for example, a commercial product results.
Neben der Temperierung des (Misch)Gefaßes kann auch die Zufuhr der Ausgangsstoffe für die Emulsionen und Dispersionen rechnergesteuert erfolgen. Über einen zentralen Rechner (Computer) können alle Prozessparameter gesteuert und kontrolliert werden. Die von den Sensoren gelieferten Messwerte werden ebenfalls vorzugsweise, wie beschrieben, dem Rechner zugeführt und rechnergestützt ausgewertet.In addition to the temperature of the (mixed) Gefaßes and the supply of starting materials for the emulsions and dispersions can be computer controlled. All process parameters can be controlled and controlled via a central computer. The measured values supplied by the sensors are also preferably fed to the computer as described and evaluated computer-aided.
Das (Misch)Gefäß kann aus beliebigem geeignetem Material aufgebaut sein. Beispiele geeigneter inerter Materialien sind Kunststoffe, Stähle wie V2A- oder V4A-Stahl oder Kupfer. Geeignete Materialien oder Werkstoffe sind dem Fachmann bekannt.The (mixed) vessel may be constructed of any suitable material. Examples of suitable inert materials are plastics, steels such as V2A or V4A steel or copper. Suitable materials or materials are known in the art.
Die Auswahl des Rührwerkzeugs, der Größe des (Misch)Gefäßes und so weiter erfolgt nach den praktischen Erfordernissen und ist durch einfache Vorversuche zu ermitteln. Die erfindungsgemäße Vorrichtung kann durch Auswahl geeigneter Rührwerkzeuge an eine Vielzahl von Anwendungen in unaufwendiger Weise angepasst werden. Die erfindungsgemäße In-Line-Prozeßkontrolle kann auch in bekannte Mischgefaße im Produktionsmaßstab integriert werden.The selection of the stirring tool, the size of the (mixing) vessel and so on is carried out according to the practical requirements and is to be determined by simple preliminary tests. The device according to the invention can be inexpensively adapted to a variety of applications by selecting suitable stirring tools. The in-line process control according to the invention can also be integrated into known mixing vessels on a production scale.
Die erfindungsgemäße Vorrichtung und das erfindungsgemäße Verfahren sind auf eine Vielzahl von Emulsionen oder Dispersionen anwendbar. Insbesondere werden erfindungsgemäße Emulsionen oder multiple Emulsionen hergestellt. Beispiele sind OW- Emulsionen, WO-Emulsionen, PO-Emulsionen, multiple Emulsionen, LC-GeIe, Liposome oder Perlglanzkonzentrate. Erfindungsgemäß sind in den Emulsionen unterschiedlichste Teilchengrößen zugänglich. Neben normalen Emulsionen können auch Nanoemulsionen
hergestellt werden, die Emulsionströpfchen mit einem mittleren Durchmesser im Bereich von 5 bis 1000 um, vorzugsweise 15 bis 300 nm, aufweisen. Auch die Herstellung von Nanodispersionen ist möglich.The apparatus and method of the present invention are applicable to a variety of emulsions or dispersions. In particular, emulsions according to the invention or multiple emulsions are prepared. Examples are OW emulsions, WO emulsions, PO emulsions, multiple emulsions, LC gels, liposomes or pearlescent concentrates. According to the invention, a wide variety of particle sizes are accessible in the emulsions. In addition to normal emulsions can also nanoemulsions having emulsion droplets having a mean diameter in the range of 5 to 1000 microns, preferably 15 to 300 nm. The production of nanodispersions is also possible.
Zur Herstellung einer wässrigen Wirkstoffträger-Nanodispersion, die mindestens einen pharmazeutischen, kosmetischen und/oder lebensmitteltechnologischen Wirkstoff enthält, können zunächst der Wirkstoff und der Wirkstoffträger auf Lipidbasis und mindestens ein Emulgator, der Lamellarstrukturen ausbildet, bei einer Temperatur oberhalb des Schmelzoder Erweichungspunktes des Wirkstoffträgers vermischt werden. Hierbei wird eine Phase B ausgebildet. Sodann kann diese Phase B mit einer wässrigen Phase A bei einer Temperatur oberhalb des Schmelz- oder Erweichungspunktes des Wirkstoffträgers vermischt werden.For the preparation of an aqueous active substance carrier nanodispersion which contains at least one pharmaceutical, cosmetic and / or food-technological active ingredient, the active substance and the lipid-based active substance carrier and at least one emulsifier which forms lamellar structures can first be mixed at a temperature above the melting or softening point of the active ingredient carrier , In this case, a phase B is formed. Then, this phase B can be mixed with an aqueous phase A at a temperature above the melting or softening point of the active ingredient carrier.
Als Wirkstoffträgerteilchen werden Teilchen auf Lipidbasis eingesetzt. Hierzu gehören Lipide und lipidähnliche Strukturen. Beispiele geeigneter Lipide sind die Mono-, Di- und Triglyceride der gesättigten geradkettigen Fettsäuren mit 12 bis 30 Kohlenstoffatomen, wie Laurinsäure, Myristinsäure, Palmitinsäure, Stearinsäure, Arachinsäure, Behensaure, Lignocerinsäure, Cerotinsäure, Melesinsäure, sowie deren Ester mit anderen mehrwertigen Alkoholen wie Ethylenglykol, Propylenglykol, Mannit, Sorbit, gesättigten Fettalkoholen mit 12 bis 22 Kohlenstoffatomen wie Laurylalkohol, Myrestylalkohol, Cetylalkohol, Stearylalkohol, Arachidylalkohol, Behenylalkohol, gesättigten Wachsalkoholen mit 24 bis 30 Kohlenstoffatomen wie Lignocerylalkohol, Cerylalkohol, Cerotylalkohol, Myrizylalkohol. Bevorzugt sind Mono-, Di-, Triglyceride, Fettalkohole, deren Ester oder Ether, Wachse, Lipidpeptide oder Mischungen davon. Insbesondere werden synthetische Mono-, Di- und Triglyceride als Einzelsubstanzen oder in Form einer Mischung, zum Beispiel in Form eines Hartfettes, eingesetzt. Glycerintrifettsäureester sind beispielsweise Glycerintrilaurat, Glycerintrimyristat, Glycerinpalmitat, Glycerintristearat oder Glycerintribehenat. Geeignete Wachse sind beispielsweise Cetylpalmitat und Cera alba (gebleichtes Wachs, DAB 9). Als Lipide können auch Polysaccharide mit oder in Einzelfällen oder Polyalkylacrylate, Polyalkylcyanoacrylate, Polyalkylvinylpyrrolidone, Acrylpolymere, Polymilchsäuren oder Polylactide eingesetzt werden.The active ingredient carrier particles used are lipid-based particles. These include lipids and lipid-like structures. Examples of suitable lipids are the mono-, di- and triglycerides of the saturated straight-chain fatty acids having 12 to 30 carbon atoms, such as lauric, myristic, palmitic, stearic, arachidic, behenic, lignoceric, cerotic, meleinic, as well as their esters with other polyhydric alcohols such as ethylene glycol , Propylene glycol, mannitol, sorbitol, saturated fatty alcohols having 12 to 22 carbon atoms, such as lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, arachidyl alcohol, behenyl alcohol, saturated wax alcohols having 24 to 30 carbon atoms, such as lignoceryl alcohol, ceryl alcohol, cerotyl alcohol, myrizyl alcohol. Preference is given to mono-, di-, triglycerides, fatty alcohols, their esters or ethers, waxes, lipid peptides or mixtures thereof. In particular, synthetic mono-, di- and triglycerides are used as individual substances or in the form of a mixture, for example in the form of a hard fat. Glycerol trifatty acid esters are, for example, glycerol trilaurate, glycerol trimyristate, glycerol palmitate, glycerol tristearate or glycerol tribehenate. Suitable waxes are, for example, cetyl palmitate and Cera Alba (bleached wax, DAB 9). Polysaccharides with or in individual cases or polyalkyl acrylates, polyalkyl cyanoacrylates, polyalkyl vinyl pyrrolidones, acrylic polymers, polylactic acids or polylactides can also be used as lipids.
Die Menge der Wirkstoffträgerteilchen, bezogen auf die gesamte wässrige Wirkstoffträger- Dispersion, beträgt vorzugsweise 0,1 bis 30 Gew.-%, besonders bevorzugt 1 bis 10 Gew.-%. Zusätzlich zu den Lipiden können Dispersionsstabilisatoren eingesetzt werden. Sie können beispielsweise in Mengen von 0,01 bis 10 Gew.-%, vorzugsweise 0,05
bis 5 Gew.-% eingesetzt werden. Beispiele geeigneter Substanzen sind Tenside, insbesondere ethoxylierte Sorbitanfettsäureester, Blockpolymere und Blockcopolymere (wie zum Beispiel Poloxamere und Poloxamine), Polyglycerinether und -ester, Lecithine verschiedenen Ursprungs (zum Beispiel Ei- oder Sojalecithin), chemisch modifizierte Lecithine (zum Beispiel hydriertes Lecithin) als auch Phospholipide und Sphingolipide, Mischungen von Lecithinen mit Phospholipiden, Sterine (zum Beispiel Cholesterin und Cholesterinderivate sowie Stigmasterin), Ester und Ether von Zuckern oder Zuckeralkoholen mit Fettsäuren oder Fettalkoholen (zum Beispiel Saccharosemonostearat), sterisch stabilsierende Substanzen wie Poloxamere und Poloxamine (Polyoxyethylen- Polyoxypropylen-Blockpolymere), ethoxylierte Sorbitanfettsäureester, ethoxylierte Mono- und Diglyceride, ethoxylierte Lipide und Lipoide, ethoxylierte Fettalkohole oder Fettsäuren und Ladungsstabilisatoren bzw. Ladungsträger wie zum Beispiel Dicetylphosphat, Phosphatidylglycerin sowie gesättigte und ungesättigte Fettsäuren, Natriumcholat, Natriumglykolcholat, Natriumtaurocholat oder deren Mischungen, Aminosäuren oder Peptisatoren wie Natriumeitrat (siehe J. S. Lucks, B. W. Müller, R. H. Müller, Int. J. Pharmaceutics 63, Seiten 183 bis 189 (1990)), Viskositätserhöhende Stoffe wie Celluloseether und -ester (zum Beispiel Methylcellulose, Hydroxyethylcellulose, Hydroxypropylcellulose, Natriumcarboxymethylcellulose), Polyvinylderivate wie Polyvinylalkohol, Polyvinylpyrrolidon, Polyvinylacetat, Alginate, Polyacrylate (zum Beispiel Carbopol), Xanthane und Pektine.The amount of the active substance carrier particles, based on the total aqueous active ingredient carrier dispersion, is preferably 0.1 to 30% by weight, particularly preferably 1 to 10% by weight. In addition to the lipids, dispersion stabilizers can be used. They may, for example, in amounts of 0.01 to 10 wt .-%, preferably 0.05 be used to 5 wt .-%. Examples of suitable substances are surfactants, in particular ethoxylated sorbitan fatty acid esters, block polymers and block copolymers (such as poloxamers and poloxamines), polyglycerol ethers and esters, lecithins of various origins (for example egg or soya lecithin), chemically modified lecithins (for example hydrogenated lecithin) as well Phospholipids and sphingolipids, mixtures of lecithins with phospholipids, sterols (for example cholesterol and cholesterol derivatives and stigmasterol), esters and ethers of sugars or sugar alcohols with fatty acids or fatty alcohols (for example sucrose monostearate), sterically stabilizing substances such as poloxamers and poloxamines (polyoxyethylene-polyoxypropylene) Block polymers), ethoxylated sorbitan fatty acid esters, ethoxylated mono- and diglycerides, ethoxylated lipids and lipids, ethoxylated fatty alcohols or fatty acids and charge stabilizers or charge carriers such as dicetyl phosphate, phosphatidylglycerol and saturated and unsaturated fatty acids, sodium cholate, sodium glycol cholate, sodium taurocholate or mixtures thereof, amino acids or peptizers such as sodium citrate (see JS Lucks, BW Müller, RH Müller, Int. J. Pharmaceutics 63, pages 183 to 189 (1990)), viscosity-increasing substances such as cellulose ethers and esters (for example methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose), polyvinyl derivatives such as polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl acetate, alginates, polyacrylates (for example Carbopol), Xanthans and pectins.
Als wässrige Phase A können Wasser, wässrige Lösungen oder Mischungen von Wasser mit wassermischbaren Flüssigkeiten wie Glycerin oder Polyethylenglycol eingesetzt werden. Weitere zusätzliche Komponenten für die wässrige Phase sind beispielsweise Mannose, Glucose, Fructose, Xylose, Trehalose, Mannit, Sorbit, Xylit oder andere Polyole wie Polyethylenglykol sowie Elektrolyte wie Natriumchlorid. Diese zusätzlichen Komponenten können in einer Menge von 0,5 bis 60, zum Beispiel 1 bis 30 Gew.-%, bezogen auf die wässrige Phase A, eingesetzt werden.As aqueous phase A, water, aqueous solutions or mixtures of water with water-miscible liquids such as glycerol or polyethylene glycol can be used. Further additional components for the aqueous phase are, for example, mannose, glucose, fructose, xylose, trehalose, mannitol, sorbitol, xylitol or other polyols, such as polyethylene glycol, and electrolytes, such as sodium chloride. These additional components can be used in an amount of 0.5 to 60, for example 1 to 30 wt .-%, based on the aqueous phase A.
Falls gewünscht, können ferner Viskositätserhöhende Stoffe oder Ladungsträger eingesetzt werden, wie Sie in EP-B-O 605 497 beschrieben sind.If desired, it is also possible to use viscosity-increasing substances or charge carriers, as described in EP-B-0 605 497.
Als Emulgatoren, die Lamellarstrukturen ausbilden, können natürliche oder synthetischeEmulsifiers that form lamellar structures can be natural or synthetic
Produkte eingesetzt werden. Auch der Einsatz von Tensidgemischen ist möglich. Beispiele geeigneter Emulgatoren sind die physiologischen Gallensalze wie Natriumcholat,Products are used. The use of surfactant mixtures is possible. Examples of suitable emulsifiers are the physiological bile salts such as sodium cholate,
Natriumdehydrocholat, Natriumdeoxycholat, Natriumglykocholat, Natriumtaurocholat.
Tierische und pflanzliche Phospholipide wie Lecithine mit ihren hydrierten Formen sowie Polypeptide wie Gelatine mit ihrem modifizierten Formen können ebenso verwendet werden.Sodium dehydrocholate, sodium deoxycholate, sodium glycocholate, sodium taurocholate. Animal and plant phospholipids such as lecithins with their hydrogenated forms as well as polypeptides such as gelatin with their modified forms can also be used.
Als synthetische grenzflächenaktive Substanzen eignen sich die Salze der Sulfobernsteinsäureester, Polyoxyethylensäurebetanester, Säurebetanester und Sorbitanether, Polyoxyethylenfettalkoholether, Polyoxyethylenstearinsäureester sowie entsprechende Mischungkondensate von Polyoxyethylen-Methpolyoxypropylenethern, ethoxylierte gesättigte Glyceride, partielle Fettsäure-Glyceride und Polyglycide. Beispiele geeigneter Tenside sind Biobase® EP und Ceralution® H.Suitable synthetic surfactants are the salts of sulfosuccinic acid esters, polyoxyethylene acid betanesters, acid betanesters and sorbitan ethers, polyoxyethylene fatty alcohol ethers, polyoxyethylene stearate esters and corresponding blend condensates of polyoxyethylene-methopolyoxypropylene ethers, ethoxylated saturated glycerides, partial fatty acid glycerides and polyglycides. Examples of suitable surfactants are Biobase® EP and Ceralution® H.
Beispiele geeigneter Emulgatoren sind ferner Glycerinester, Polyglycerinester, Sorbitanester, Sorbitolester, Fettalkohole, Propylenglykolester, Alkylglucositester, Zuckerester, Lecithin, Silikoncopolymere, Wollwachs und deren Mischungen oder Derivate. Glycerinester, Polyglycerinester, Alkoxylate und Fettalkohole sowie Isoalkohole können sich beispielsweise ableiten von Rizinusfettsäure, 12-Hydroxystearinsäure, Isostearinsäure, Ölsäure, Linolsäure, Linolensäure, Stearinsäure, Myristinsäure, Laurinsäure und Caprinsäure. Neben den genannten Estern können auch Succinate, Amide oder Ethanolamide der Fettsäuren vorliegen. Als Fettsäurealkoxylate kommen insbesondere die Ethoxylate, Propoxylate oder gemischten Ethoxylate/Propoxylate in Betracht.Examples of suitable emulsifiers are also glycerol esters, polyglycerol esters, sorbitan esters, sorbitol esters, fatty alcohols, propylene glycol esters, alkylglucositesters, sugar esters, lecithin, silicone copolymers, wool wax and mixtures thereof or derivatives. Glycerol esters, polyglycerol esters, alkoxylates and fatty alcohols and isoalcohols can be derived, for example, from castor fatty acid, 12-hydroxystearic acid, isostearic acid, oleic acid, linoleic acid, linolenic acid, stearic acid, myristic acid, lauric acid and capric acid. In addition to the stated esters, succinates, amides or ethanolamides of the fatty acids may also be present. Particularly suitable fatty acid alkoxylates are the ethoxylates, propoxylates or mixed ethoxylates / propoxylates.
Auch zur Herstellung der erfindungsgemäßen kosmetischen Emulsionen werden in der Regel Emulgatoren verwendet. Beispiele geeigneter Emulgatoren sind Glycerinester, Polyglycerinester, Sorbitanester, Sorbitolester, Fettalkohole, Propylenglykolester, Alkylglucosidester, Zuckerester, Lecithin, Silikoncopolymere, Wollwachs und ihre Mischungen und Derivate. Glycerinester, Polyglycerinester, Alkoxylate und Fettalkohole sowie Isoalkohole können sich beispielsweise ableiten von Rhizinusfettsäure, 12- Hydroxystearinsäure, Isostearinsäure, Ölsäure, Linolsäure, Linolensäure, Stearinsäure, Myrestinsäure, Maurinsäure und Caprinsäure. Neben den genannten Estern können auch Succinate, Amide oder Ethanolamide der Fettsäuren vorliegen. Als Fettsäurealkoxylate kommen insbesondere die Ethoxylate, Propoxylate oder gemischten Ethoxylate/Propoxylate in Betracht. Ferner können Emulgatoren eingesetzt werden, die Lamelarstrukturen ausbilden. Beispiele derartiger Emulgatoren sind die physiologischen Gallensalze wie Natriumcheolat, Natriumdehydrocheolat, Natriumdeoxycheolat, Natriumglycochealat, Natriumtaurochealat. Tierische und pflanzliche Phospholipide wie
Lecithine mit Ihren hydrierten Formen sowie Polypeptide wie Gelatine mit ihren modifizierten Formen können ebenso verwendet werden.Emulsifiers are also generally used to prepare the cosmetic emulsions according to the invention. Examples of suitable emulsifiers are glycerol esters, polyglycerol esters, sorbitan esters, sorbitol esters, fatty alcohols, propylene glycol esters, alkylglucoside esters, sugar esters, lecithin, silicone copolymers, wool wax and their mixtures and derivatives. Glycerol esters, polyglycerol esters, alkoxylates and fatty alcohols and isoalcohols can be derived, for example, from castor fatty acid, 12-hydroxystearic acid, isostearic acid, oleic acid, linoleic acid, linolenic acid, stearic acid, myristic acid, mauric acid and capric acid. In addition to the stated esters, succinates, amides or ethanolamides of the fatty acids may also be present. Particularly suitable fatty acid alkoxylates are the ethoxylates, propoxylates or mixed ethoxylates / propoxylates. It is also possible to use emulsifiers which form lamellar structures. Examples of such emulsifiers are the physiological bile salts such as sodium cheolate, sodium dehydrocheolate, sodium deoxycheolate, sodium glycochelate, sodium taurochalate. Animal and vegetable phospholipids like Lecithins with their hydrogenated forms as well as polypeptides such as gelatin with their modified forms can also be used.
Als synthetische grenzflächenaktive Substanzen eignen sich die Salze der Sulfobernsteinsäureester, Polyoxiethylensäurebethanester, Säurebethanester und Sorbitanether, Polyoxiethylenfettalkoholether, Polyoxiethylenstearinsäureester sowie entsprechende Mischungskondensate von Polyoxiethylen-methpolyoxipropylenethern, ethoxylierte gesättigte Glyceride, partielle Fettsäure-Glyceride und Polyglycide. Beispiele geeigneter Tenside sind Biobase® EP und Ceralution® H.Suitable synthetic surfactants are the salts of sulfosuccinic, Polyoxiethylensäurebethanester, Säurebethanester and sorbitan, Polyoxiethylenfettalkoholether, Polyoxiethylenstearinsäureester and corresponding mixture condensates of Polyoxiethylen-methpolyoxipropylenethern, ethoxylated saturated glycerides, partial fatty acid glycerides and polyglycides. Examples of suitable surfactants are Biobase ® EP and Ceralution ® H.
Lipide und Emulgatoren werden vorzugsweise in einem Gewichtsverhältnis von 50: 1 bis 2: 1, vorzugsweise 15:1 bis 30:1 eingesetzt.Lipids and emulsifiers are preferably used in a weight ratio of 50: 1 to 2: 1, preferably 15: 1 to 30: 1.
Die pharmazeutischen, kosmetischen und/oder lebensmitteltechnologischen Wirkstoffe werden, bezogen auf die Phase B, vorzugsweise in einer Menge von 0,1 bis 80 Gew.-%, besonders bevorzugt 1 bis 10 Gew.-% eingesetzt.The pharmaceutical, cosmetic and / or food-technological active ingredients are, based on the phase B, preferably used in an amount of 0.1 to 80 wt .-%, particularly preferably 1 to 10 wt .-%.
Nachfolgend werden beispielhaft pharmazeutische Wirkstoffe aufgeführt, die beispielsweise in freier Form, als Salz, Ester oder Ether eingesetzt werden können:The following are exemplary pharmaceutical active ingredients listed, which can be used for example in free form, as a salt, ester or ether:
Analgetika/Antirheumatika, wie Morphin, Copdein, Piritamid, Fentanyl und Fentanylderivate, Levomethadon, Tramadol, Diclofenac, Ibuprofen, Indometacin, Naproxen, Piroxicam, Penicillamin; Antiallergika, wie Pheniramin, Dimetinden, Terfenadin, Asternizol, Loratidin, Doxylamin, Meclozin, Bamipin, Clemastin; Antibiotika / Chemotherapeutika, wie Polypetidantibiotika wie Colistin, Polymyxin B, Teicplanin, Vancomycin; Malariamittel wie Chinin, Halofantrin, Mefloquin, Chloroquin, Virustatika wie Ganciclovir, Foscarnet, Zidovudin, Aciclovir und andere wie Dapson, Fosfomycin, Fusafungüi, Trimetoprim; Antiepileptika, wie Phenytoin, Mesuximid, Ethosuximid, Primidon, Phenobarbital, Valproinsäure, Carbamazepin, Clonazepam; Antimykotika, wie intern: Nystatin, Natarrycin, Amphotericin B, Flucytoan, Miconazol, Fluconazol, Itraconazol; extern außerdem: Clotrimazol, Econazol, Tioconazol, Fenticonazol, Bifonazol, Oxiconazol, Ketoconazol, isoconazol, Tlnattat; Corticoide (Interna), wie Aldosteron Fludrocortison, Betametason, Dexametason, Triamcinolon, Fluocortolon, Hydroxycortison, Prednisolon, Prednyliden, Cloprednol, Methylprednisolon; Dermatika, wie Antibiotika: Tetracyclin, Erythromycin, Neomycin, Gentamycin, Clindamiycin, Framycetin, Tyrothricin, Chlortetracyclin Mipirocin, Fusidnsäure; Virustatika wie oben,
außerdem: Podohyllotoxin, Vidarabin, Tromantadin; Corticoide wie oben, außerdem: Amcinonid, Flupredniden, Alclometason, Clobetasol, Diflorason, Halcinonid, Fluocinolon, Clocortolon, Flumetason, Difluocortolon, Fludroxycortid, Halometason, Desoximtason, Fluocinolid, Fluocortinbutyl, Flupredniden, Prednicarbat, Desonid; Diagnostika, wie radioaktive Isotope wie Te99m, InI 11 oder 1131, kovalent gebunden an Lipide oder Lipoide oder andere Moleküle oder in Komplexen, hochsubstituierte iodhaltige Verbindungen wie zum Beispiel Lipide; Hämostyptika, wie Blutungsgerinnungsfaktoren VIII, DC; Hypnotika, Sedativa, wie Cyclobarbital, Pentobarbital, Phenobarbital, Methaqualon, Benzodiazepine (Flurazepam, Midazolam, Netrazepam, Lormetazepam, Flunitrazepam, Trazolam, Brotizolam, Temazepam, Loprazolam); Hypophysen-, Hypothalamushormone, regulatorische Peptide und ihre Hemmstoffe, wie Corticotrophin, Tetracosactid, Choriongonadotropin, Urofollitropin, Urogonadotropin, Somatropin, Metergolin, Bromocriptin, Terlipressin, Desmopressin, Oxrtocin, Argipressin, Ornipressin, Leuprorelin, Triptorelin, Gonadorelin, Buserelin, Nafarelin, Goselerin, Somatostatin; Immuntherapeutika und Zytokine, wie Dimepranol-4-acetatamidobenzoat, Thymopentin, α-Interferon, ß-Interferon, Filgrastim, Interleukine, Azathioprin, Ciclosporin; Lokalanaesthetika, wie intern: Butanilicain, Mepivacain, Bupivacain, Etidocain, Lidocain, Articain, Prilocain; extern außerdem: Propipocain, Oxybuprocain, Etracain, Benzocain; Migränemittel, wie Proxibarbal, Lisurid, Methysergid, Dihydroergotamin, Clonidin, Ergotamin, Pizotifen; Narkosemittel, wie Methohexital, Propofol, Etomidat, Ketamin, Alfentanil, Thiopental, Droperidol, Fentanyl; Nebenschilddrüsenhormone, Calciumstoffwechselregulatoren, wie Dihydrotachysterol, Calcitonin, Clodronsäure, Etidronsäure; Opthalmika, wie Atropin, Cyclodrin, Cyclopentolat, Homatropin, Tronicamid, Scopolamin, Pholedrin, Edoxudin, Idouridin, Tromantadin, Aciclovir, Acetazolamid, Diclofenamid, Carteolol, Timolol, Metipranolol, Betaxolol, Pindolol, Befunolol, Bupranolol, Levobununol, Carbachol, Pilocarpin, Clonidin, Neostigmin; Psychopharmaka, wie Benzodiazepne (Lorazepam, Diazepam), Clomethiazol; Schilddrüsentherapeutika, wie 1 -Thyroxin, Carbimazol, Thiamazol, Propylthiouracil; Sera, Immunglobuline, Impfstoffe, wie Immunglobuline allgemein und spezifisch wie Hepatitis- Typen, Röteln, Cytomegalie, Tollwut; FSME, VaricellaZoster, Tetanus, Rhesusfaktoren, Immunsera wie Botulismus- Antitoxin, Diphterie, Gasbrand, Schlangengift, Skorpiongift, Impfstoffe wie Influenza, Tuberkulose Cholera, Diphterie, Hepatitis-Typen, FSME, Röteln, Hämophilus influenzae, Masern, Neisseria, Mumps, Poliomyelitis, Tetanus, Tollwut, Typhus; Sexualhormone und ihre Hemmstoffe, wie Anabolika, Androgene, Antiandrogene, Gestagene, Estrogene, Antiestrogene (Tamoxifen etc.); Zystostatika und Metastasenhemmer, wie Alkylantien wie Nimustin, Melphalan, Carmustin, Lomustin,
Cyclophosphamid, Ifosfamid, Trofosfamid, Chlorambucil, Busulfan, Treosulfan, Predninmustin, Thiotepa,Analgesics / antirheumatics such as morphine, copdein, piritamide, fentanyl and fentanyl derivatives, levomethadone, tramadol, diclofenac, ibuprofen, indomethacin, naproxen, piroxicam, penicillamine; Antiallergic agents such as pheniramine, dimetinden, terfenadine, asternizole, loratidine, doxylamine, meclozin, bamipin, clemastine; Antibiotics / chemotherapeutics such as polypetid antibiotics such as colistin, polymyxin B, teicplanin, vancomycin; Antimalarials such as quinine, halofantrine, mefloquine, chloroquine, antivirals such as ganciclovir, foscarnet, zidovudine, acyclovir and others such as dapsone, fosfomycin, fusafungi, trimetoprim; Anticonvulsants such as phenytoin, mesuximide, ethosuximide, primidone, phenobarbital, valproic acid, carbamazepine, clonazepam; Antifungals such as internally: nystatin, natarrycin, amphotericin B, flucytoan, miconazole, fluconazole, itraconazole; external also: clotrimazole, econazole, tioconazole, fenticonazole, bifonazole, oxiconazole, ketoconazole, isoconazole, tlnattate; Corticoids (internals), such as aldosterone fludrocortisone, betametasone, dexametasone, triamcinolone, fluocortolone, hydroxycortisone, prednisolone, prednylidene, cloprednol, methylprednisolone; Dermatics, such as antibiotics: tetracycline, erythromycin, neomycin, gentamycin, clindamiycin, framycetin, tyrothricin, chlortetracycline mipirocin, fusidic acid; Antivirals as above, also: podohyllotoxin, vidarabine, tromantadine; Corticoids as above, also: amcinonide, flupredniden, alclometasone, clobetasol, diflorasone, halcinonide, fluocinolone, clocortolone, flumetasone, difluocortolone, fludroxycortide, halometasone, desoximtasone, fluocinolide, fluocortinbutyl, flupredniden, prednicarbate, desonide; Diagnostics such as radioactive isotopes such as Te99m, InI 11 or 1131 covalently linked to lipids or lipids or other molecules or in complexes, highly substituted iodine-containing compounds such as lipids; Hemostatic agents, such as bleeding factors VIII, DC; Hypnotics, sedatives such as cyclobarbital, pentobarbital, phenobarbital, methaqualone, benzodiazepines (flurazepam, midazolam, netrazepam, lormetazepam, flunitrazepam, trazolam, Brotizolam, temazepam, loprazolam); Pituitary and hypothalamic hormones, regulatory peptides and their inhibitors such as corticotrophin, tetracosactide, chorionic gonadotropin, urofollitropin, urothonototropin, somatropin, metergoline, bromocriptine, terlipressin, desmopressin, oxrtocin, argipressin, ornipressin, leuprorelin, triptorelin, gonadorelin, buserelin, nafarelin, goselerin, somatostatin; Immunotherapeutics and cytokines, such as dimepranol-4-acetatamidobenzoate, thymopentin, α-interferon, β-interferon, filgrastim, interleukins, azathioprine, ciclosporin; Local anesthetics, such as internally: butanilicain, mepivacaine, bupivacaine, etidocaine, lidocaine, articaine, prilocaine; external also: propipocaine, oxybuprocaine, etracaine, benzocaine; Migraine agents such as proxibarbal, lisuride, methysergide, dihydroergotamine, clonidine, ergotamine, pizotifen; Anesthetics such as methohexital, propofol, etomidate, ketamine, alfentanil, thiopental, droperidol, fentanyl; Parathyroid hormones, calcium metabolism regulators such as dihydrotachysterol, calcitonin, clodronic acid, etidronic acid; Opthalmics such as atropine, cyclodrin, cyclopentolate, homatropin, tronicamide, scopolamine, pholedrine, edoxudine, idouridin, tromantadine, acyclovir, acetazolamide, diclofenamide, carteolol, timolol, metipranolol, betaxolol, pindolol, befunolol, bupranolol, levobununol, carbachol, pilocarpine, clonidine , Neostigmine; Psychotropic drugs, such as benzodiazepines (lorazepam, diazepam), clomethiazole; Thyroid therapeutics such as 1-thyroxine, carbimazole, thiamazole, propylthiouracil; Sera, immunoglobulins, vaccines such as immunoglobulins in general and specific such as hepatitis types, rubella, cytomegalovirus, rabies; TBE, varicella zoster, tetanus, Rhesus factors, immune serums such as botulism antitoxin, diphtheria, gas gangrene, snake venom, scorpion venom, vaccines such as influenza, tuberculosis cholera, diphtheria, hepatitis types, TBE, rubella, hemophilus influenzae, measles, neisseria, mumps, poliomyelitis, Tetanus, rabies, typhus; Sex hormones and their inhibitors, such as anabolic steroids, androgens, antiandrogens, progestogens, estrogens, antiestrogens (tamoxifen etc.); Cystostatic agents and metastasis inhibitors such as alkylating agents such as Nimustin, Melphalan, Carmustine, Lomustine, Cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, busulfan, treosulfan, predninmustine, thiotepa,
Antimetabolite wie Cytarabin, Fluorouracil, Methotrexat, Mercaptopurin, Tioguanin, Alkaloide wie Vinblastin, Vincristin, Vindesin; Antibiotika wie Aclarubicin, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mitomycin, Plicamycin,Antimetabolites such as cytarabine, fluorouracil, methotrexate, mercaptopurine, tioguanine, alkaloids such as vinblastine, vincristine, vindesine; Antibiotics such as aclarubicin, bleomycin, dactinomycin, daunorubicin, epirubicin, idarubicin, mitomycin, plicamycin,
Komplexe von Nebengruppenelementen (zum Beispiel Ti, Zr, V, Nb, Ta, Mo, W, Pt) wie Carboplatin, Cisplatin und Metallocenverbindungen wie Titanocendichlorid Amsacrin, Dacarbazin, Estramustin, Etoposid, Hydroxycarbamid, Mitoxynthron, Procarbazin, Temiposid Alkylamidophospholipide (beschrieben in J. M. Zeidler, F. Emling, W. Zimmermann und H. J. Roth, Archiv der Pharmazie, 324 (1991), 687)Complexes of subgroup elements (for example, Ti, Zr, V, Nb, Ta, Mo, W, Pt) such as carboplatin, cisplatin and metallocene compounds such as titanocene dichloride amsacrine, dacarbazine, estramustine, etoposide, hydroxycarbamide, mitoxynthrone, procarbazine, temiposide, alkylamidophospholipids (described in JM Zeidler, F. Emling, W. Zimmermann and HJ Roth, Archiv der Pharmazie, 324 (1991), 687)
Etherlipide wie Hexadecylphosphocholin, Dmofosin und Analoga, beschrieben in R. Zeisig, D. Arndt und H. Brachwitz, Pharmazie 45 (1990), 809 bis 818.Etherlipids such as hexadecylphosphocholine, dmofosine and analogs described in R. Zeisig, D. Arndt and H. Brachwitz, Pharmacy 45 (1990), 809-818.
Geeignete Wirkstoffe sind beispielsweise auch Dichlorphenac, Ibuprofen, Acetylsalicylsäure, Salicylsäure, Erythromycin, Ketoprofen, Cortison, Glucocorticoide.Suitable active ingredients are, for example, also dichlorphenac, ibuprofen, acetylsalicylic acid, salicylic acid, erythromycin, ketoprofen, cortisone, glucocorticoids.
Weiterhin geeignet sind kosmetische Wirkstoffe, die insbesondere oxidations- oder hydrolyseempfindlich sind wie beispielsweise Polyphenole. Hier seien genannt Catechine (wie Epicatechin, Epicatechin-3-gallat, Epigallocatechin, Epigallocatechin-3-gallat), Flavonoide (wie Luteolin, Apigenin, Rutin, Quercitin, Fisetin, Kaempherol, Rhametin), Isoflavone (wie Genistein, Daidzein, Glycitein, Prunetin), Cumarine (wie Daphnetin, Umbelliferon), Emodin, Resveratrol, Oregonin.Also suitable are cosmetic active ingredients which are particularly susceptible to oxidation or hydrolysis, for example polyphenols. Catechins (such as epicatechin, epicatechin-3-gallate, epigallocatechin, epigallocatechin-3-gallate), flavonoids (such as luteolin, apigenin, rutin, quercitin, fisetin, kaempherol, rhametin), isoflavones (such as genistein, daidzein, glycitein, Prunetin), coumarins (such as daphnetin, umbelliferone), emodin, resveratrol, oregonin.
Geeignet sind Vitamine wie Retinol, Tocopherol, Ascorbinsäure, Ribofiavin, Pyridoxin. Geeignet sind ferner Gesamtextrakte aus Pflanzen, die u.a. obige Moleküle oder Molekülklassen enthalten.Suitable are vitamins such as retinol, tocopherol, ascorbic acid, ribofiavine, pyridoxine. Also suitable are whole extracts from plants, which i.a. contain the above molecules or classes of molecules.
Bei den Wirkstoffen handelt es sich gemäß einer Ausführungsform der Erfindung um Lichtschutzfilter. Diese können als organische Lichtschutzfilter bei RaumtemperaturThe active substances are, according to one embodiment of the invention, light protection filters. These can be used as organic sunscreen at room temperature
(250C) in flüssiger oder fester Form vorliegen. Geeignete Lichtschutzfilter (UV-Filter) sind beispielsweise Verbindungen auf Basis von Benzophenon, Diphenylcyanacrylat oder p-(25 0 C) in liquid or solid form. Suitable light protection filters (UV filters) are, for example, compounds based on benzophenone, diphenyl cyanoacrylate or
Aminobenzoesäure. Konkrete Beispiele sind (INCI- oder CTFA-Bezeichnungen)Amino benzoic acid. Concrete examples are (INCI or CTFA designations)
Benzophenone-3, Benzophenone-4, Benzophenone-2, Benzophenone-6, Benzophenone-9, Benzophenone-1, Benzophenone-11, Etocrylene, Octocrylene, PEG-25 PABA,Benzophenone-3, Benzophenone-4, Benzophenone-2, Benzophenone-6, Benzophenone-9, Benzophenone-1, Benzophenone-11, Etocrylene, Octocrylene, PEG-25 PABA,
Phenylbenzimidazole Sulfonic Acid, Ethylhexyl Methoxycinnamate, Ethylhexyl Dimethyl
PABA, 4-Methylbenzylidene Camphor, Butyl Methoxydibenzoylmethane, Ethylhexyl Salicylate, Homosalate sowie Methylene-Bis-Benzotriazolyl Tetramethylbutylphenol (2,2'- Methylen-bis- {6-(2H-benzoetriazol-2-yl)-4-( 1 , 1 ,3 ,3 -tetramethylbutyl)-phenol } , 2-Phenylbenzimidazole sulfonic acid, ethylhexyl methoxycinnamate, ethylhexyl dimethyl PABA, 4-methylbenzylidene camphor, butyl methoxydibenzoylmethane, ethylhexyl salicylates, homosalates, and methylene-bis-benzotriazolyl tetramethylbutylphenol (2,2'-methylene-bis- {6- (2H-benzoetriazol-2-yl) -4- (1, 1 , 3, 3-tetramethylbutyl) -phenol}, 2-
Hydroxy-4-methoxybenzophenon-5-sulfonsäure und 2,4,6-Trianilino-p-(carbo-2'- ethylhexyl- l'-oxi)-l, 3, 5-triazin.Hydroxy-4-methoxybenzophenone-5-sulfonic acid and 2,4,6-trianilino-p- (carbo-2'-ethylhexyl-1-oxi) -l, 3, 5-triazine.
Weitere organische Lichtschutzfilter sind Octyltriazone, Avobenzone, Octylmethoxycinnamate, Octylsalicylate, Benzotriazole und Triazine.Other organic sunscreen filters are octyltriazone, avobenzone, octylmethoxycinnamates, octylsalicylates, benzotriazoles and triazines.
Gemäß einer weiteren Ausführungsform der Erfindung werden als Wirkstoffe Antischuppen-Wirkstoffe eingesetzt, wie sie üblicherweise in kosmetischen oder pharmazeutischen Formulierungen vorliegen. Ein Beispiel hierfür ist Piroctone Olamine ( 1 -Hydroxy-4-methyl-6-(2,4,4-dimethylpentyl)-2( 1 H)-pyridone; vorzugsweise in Kombination mit 2-Aminoethanol (1:1)). Weitere geeignete Mittel zur Behandlung von Hautschuppen sind dem Fachmann bekannt.According to a further embodiment of the invention, anti-dandruff agents are used as active ingredients, as they are usually present in cosmetic or pharmaceutical formulations. An example of this is Piroctone Olamine (1-hydroxy-4-methyl-6- (2,4,4-dimethylpentyl) -2 (1H) -pyridone, preferably in combination with 2-aminoethanol (1: 1)). Other suitable agents for the treatment of dander are known in the art.
Weitere mögliche Inhaltstoffe der Emulsionen sind hydrophil beschichtete Mikropigmente, Elektrolyte, Glycerin, Polyethylenglykol, Propylenglykol, Bariumsulfat, Alkohole, Wachse, Metallseifen, Magnesiumstearat, Vaseline oder andere Inhaltsstoffe. Beispielsweise können weiterhin Parfüms, Parfumöle oder Parfumaromen zugesetzt werden. Geeignete kosmetische Wirkstoffe beispielsweise Polyphenole und davon abgeleitete Verbindungen. Geeignete Vitamine sind Retinol, Tocopherol, Ascorbinsäure, Riboflavin und Pyridoxin.Other possible ingredients of the emulsions are hydrophilic coated micropigments, electrolytes, glycerol, polyethylene glycol, propylene glycol, barium sulfate, alcohols, waxes, metal soaps, magnesium stearate, vaseline or other ingredients. For example, it is also possible to add perfumes, perfume oils or perfume flavors. Suitable cosmetic agents, for example polyphenols and compounds derived therefrom. Suitable vitamins are retinol, tocopherol, ascorbic acid, riboflavin and pyridoxine.
Als Wirkstoffe kommen zudem beispielsweise alle oxidationssensiblen Wirkstoffe wie Tocopherol in Betracht.As active ingredients, for example, all oxidation-sensitive active ingredients such as tocopherol come into consideration.
Gemäß einer weiteren Ausführungsform der Erfindung werden organische Farbstoffe als Wirkstoffe bzw. an Stelle von Wirkstoffen eingesetzt.According to a further embodiment of the invention, organic dyes are used as active ingredients or instead of active substances.
Mit dem erfindungsgemäßen Verfahren können alle bekannten und geeigneten Wasser-in- Öl-Emulsionen oder Öl-in-Wasser-Emulsionen hergestellt werden. Dazu können die nach den beschriebenen Emulgatoren und weiteren Inhaltsstoffe eingesetzt werden. Ferner ist die Herstellung von Polyol-in-Öl-Emulsionen möglich. Hierbei können beliebige geeignete Polyole eingesetzt werden.
In den Emulsionen können die Anteile der zwei Hauptphasen in weiten Bereichen variiert werden. Beispielsweise liegen 5 bis 95 Gew.-%, vorzugsweise 10 bis 90 Gew.-%, insbesondere 20 bis 80 Gew.-% der jeweiligen Phasen vor, wobei die Gesamtmenge 100 Gew.-% ergibt.All known and suitable water-in-oil emulsions or oil-in-water emulsions can be prepared by the process according to the invention. These can be used after the emulsifiers described and other ingredients. Furthermore, the preparation of polyol-in-oil emulsions is possible. Any suitable polyols can be used here. In the emulsions, the proportions of the two main phases can be varied within wide limits. For example, from 5 to 95% by weight, preferably from 10 to 90% by weight, in particular from 20 to 80% by weight, of the respective phases are present, the total amount being 100% by weight.
Die beschriebene P/O-Emulsion kann auch in Wasser oder eine Wasser-in-Öl-Emulsion emulgiert werden. Dabei resultiert eine Polyol-in-Öl-inWasser-Emulsion (P/O/W- Emulsion), die mindestens eine beschriebene Emulsion und zusätzlich mindestens eine wässrige Phase enthält. Derartige multiple Emulsionen können im Aufbau den in DE-A-43 41 113 und DE-A-43 41114 beschriebenen Emulsionen entsprechen.The described P / O emulsion can also be emulsified in water or a water-in-oil emulsion. This results in a polyol-in-oil-in-water emulsion (P / O / W emulsion) containing at least one described emulsion and additionally at least one aqueous phase. Such multiple emulsions may correspond in structure to the emulsions described in DE-A-43 41 113 and DE-A-43 41114.
Beim Einbringen der erfindungsgemäßen P/O-Emulsion in Wasser oder wässrige Systeme kann das Gewichtsverhältnis der einzelnen Phasen in weiten Bereichen variiert werden. Vorzugsweise beträgt in der letztendlich erhaltenen P/O/W-Emulsion der Gewichtsanteil der P/O-Emulsion 0,01 bis 80 Gew.-%, besonders bevorzugt 0,1 bis 70 Gew.-%, insbesondere 1 bis 30 Gew.-%, bezogen auf die gesamte P/O/W-Emulsion.When introducing the P / O emulsion according to the invention into water or aqueous systems, the weight ratio of the individual phases can be varied within wide limits. In the finally obtained P / O / W emulsion, the weight fraction of the P / O emulsion is preferably from 0.01 to 80% by weight, particularly preferably from 0.1 to 70% by weight, in particular from 1 to 30% by weight. %, based on the total P / O / W emulsion.
Beim Einbringen der erfindungsgemäßen P/O-Emulsion in eine O/W-Emulsion beträgt der Anteil der P/O-Emulsion vorzugsweise 0,01 bis 60 Gew.-%, besonders bevorzugt 0,1 bis 40 Gew.-%, insbesondere 1 bis 30 Gew.-%, bezogen auf die letztendlich erhaltene P/O/W- Emulsion. In der O/W-Emulsion, die hierzu verwendet wird, beträgt der Ölanteil vorzugsweise 1 bis 80 Gew.-%, besonders bevorzugt 1 bis 30 Gew.-%, bezogen auf die eingesetzte O/W-Emulsion. Anstelle einer P/O-Emulsion kann auch eine W/O-Emulsion eingebracht werden, was zu einer W/O/W-Emulsion führt. Die einzelnen Phasen der Emulsionen können noch übliche für die einzelnen Phasen bekannte Inhaltsstoffe aufweisen. Beispielsweise können die einzelnen Phasen weitere in diesen Phasen lösliche pharmazeutische oder kosmetische Wirkstoffe enthalten. Die wässrige Phase kann beispielsweise organische lösliche Lichtschutzfilter, hydrophil gecoatetes Micropigment, Elektrolyte, Alkohole usw. enthalten. Einzelne oder alle der Phasen können zudem Feststoffe enthalten, die vorzugsweise ausgewählt sind aus Pigmenten oder Micropigmenten, Mikrosphären, Silikagel und ähnlichen Stoffen. Die Ölphase kann beispielsweise organisch modifizierte Tonmineralien, hydrophob gecoatete (Micro)Pigmente, organische öllösliche Lichtschutzfilter, öllösliche kosmetische Wirkstoffe, Wachse, Metallseifen wie Magnesiumstearat, Vaseline oder Gemische davon enthalten. Als (Micro)Pigmente können Titandioxid, Zinkoxid und Bariumsulfat sowie Wollastonit, Kaolin, Talk, Al2O3, Bismutoxidchlorid, micronisiertes Polyethylen,
Glimmer, Ultramarin, Eosinfarben, Azofarbstoffe, genannt werden. Insbesondere Titandioxid oder Zinkoxid sind in der Kosmetik als Lichtschutzfilter gebräuchlich und lassen sich mittels der erfindungsgemäßen Emulsionen besonders glatt und gleichmäßig auf die Haut auftragen. Mikrosphären oder Silicagel können als Träger für Wirkstoffe eingesetzt werden, und Wachse können beispielsweise als Grundlage für Polituren verwendet werden.When introducing the P / O emulsion according to the invention into an O / W emulsion, the proportion of the P / O emulsion is preferably 0.01 to 60% by weight, particularly preferably 0.1 to 40% by weight, in particular 1 to 30 wt .-%, based on the final P / O / W emulsion. In the O / W emulsion used for this purpose, the oil content is preferably 1 to 80% by weight, particularly preferably 1 to 30% by weight, based on the O / W emulsion used. Instead of a P / O emulsion, a W / O emulsion can also be introduced, which leads to a W / O / W emulsion. The individual phases of the emulsions may still have conventional ingredients known for the individual phases. For example, the individual phases may contain further pharmaceutical or cosmetic active substances which are soluble in these phases. The aqueous phase may contain, for example, organic soluble sunscreen, hydrophilically coated micropigment, electrolytes, alcohols, etc. Also, any or all of the phases may contain solids which are preferably selected from pigments or micropigments, microspheres, silica gel, and the like. The oil phase may contain, for example, organically modified clay minerals, hydrophobically coated (micro) pigments, organic oil-soluble light protection filters, oil-soluble cosmetic agents, waxes, metal soaps such as magnesium stearate, vaseline or mixtures thereof. As (micro) pigments, titanium dioxide, zinc oxide and barium sulfate as well as wollastonite, kaolin, talc, Al 2 O 3 , bismuth oxychloride, micronized polyethylene, Mica, ultramarine, eosin, azo dyes. Titanium dioxide or zinc oxide, in particular, are customary in cosmetics as light protection filters and can be applied particularly smoothly and evenly to the skin by means of the emulsions according to the invention. Microspheres or silica gel can be used as carriers for drugs, and waxes can be used, for example, as a base for polishes.
Die Wasserphase kann darüber hinaus Glycerin, Polyethylenglykol, Propylenglykol,The water phase may also contain glycerol, polyethylene glycol, propylene glycol,
Ethylenglykol und ähnliche Verbindungen sowie Derivate davon enthalten.Ethylene glycol and similar compounds and derivatives thereof.
Die Verwendung von üblichen Hilfs- und Zusatzstoffen in den Emulsionen ist demThe use of customary auxiliaries and additives in the emulsions is the
Fachmann bekannt.Specialist known.
Als wässrige Phase können Wasser, wässrige Lösungen oder Mischungen von Wasser mit wassermischbaren Flüssigkeiten wie Glycerin oder Polyethylenglykol eingesetzt werden. Ferner können in der wässrigen Phase Elektrolyte wie Natriumchlorid enthalten sein. Falls gewünscht, können ferner Viskositätserhöhende Stoffe oder Ladungsträger eingesetzt werden, wie sie in der EP-B-0605 497 beschrieben sind.
As the aqueous phase, water, aqueous solutions or mixtures of water with water-miscible liquids such as glycerol or polyethylene glycol can be used. Further, electrolytes such as sodium chloride may be contained in the aqueous phase. If desired, it is also possible to use viscosity-increasing substances or charge carriers, as described in EP-B-0605 497.
Claims
1. Vorrichtung zur In-Line-Prozesskontrolle bei der Herstellung von Emulsionen oder Dispersionen, umfassend ein Gefäß zur Aufnahme einer Emulsion oder Dispersion, ein in dem Gefäß angeordnetes Rührwerkzeug zum Rühreintrag in die Emulsion oder Dispersion, eine Vorrichtung zur kontinuierlichen Messung des Rühreintrags, in dem Gefäß angeordnete Messsonden zur kontinuierlichen Messung der Temperatur und der Leitfähigkeit der Emulsion oder Dispersion sowie eine Aufzeichnungsvorrichtung zur kontinuierlichen Aufzeichnung des Rühreintrags, der Temperatur und der Leitfähigkeit.1. An apparatus for in-line process control in the preparation of emulsions or dispersions, comprising a vessel for receiving an emulsion or dispersion, an arranged in the vessel agitator for stirring entry into the emulsion or dispersion, a device for continuously measuring the Rühreintrags, in measuring probes arranged in the vessel for the continuous measurement of the temperature and the conductivity of the emulsion or dispersion; and a recording device for the continuous recording of the stirring, the temperature and the conductivity.
2. Vorrichtung nach Anspruch 1, dadurch gekennzeichnet, dass das Rührwerkzeug mindestens ein von einem Rührmotor über eine gedrehte Rührerachse angetriebenes2. Apparatus according to claim 1, characterized in that the stirring tool driven at least one of a stirring motor via a rotated agitator axis
Rührelement aufweist und die Messung des Rühreintrags durch Messung der Drehzahl der Rührerachse erfolgt.Has stirring element and the measurement of the Rühreintrags carried out by measuring the speed of the stirrer axis.
3. Vorrichtung nach Anspruch 2, dadurch gekennzeichnet, dass die Rührerachse in ihrem Verlauf eine elektrische Isolierung der Art aufweist, dass Rührelement und3. A device according to claim 2, characterized in that the stirrer axis in its course has an electrical insulation of the type that stirring element and
Rührmotor voneinander elektrisch isoliert sind.Stirring motor are electrically isolated from each other.
4. Vorrichtung nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass sie zur diskontinuierlichen Herstellung von Emulsionen oder Dispersionen im Labor-, Technikums- oder Produktionsmaßstäb dient.4. Device according to one of claims 1 to 3, characterized in that it serves for the discontinuous production of emulsions or dispersions in the laboratory, Technikums- or Produktionsmaßstäb.
5. Vorrichtung nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, dass sie eine Vorrichtung zum Temperieren des Gefäßes aufweist.5. Device according to one of claims 1 to 4, characterized in that it comprises a device for tempering the vessel.
6. Vorrichtung nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, dass sie einen Rechner als Steuereinheit aufweist und der Rühreintrag und gegebenenfalls die Temperierung des Gefäßes rechnergesteuert sind.6. Device according to one of claims 1 to 5, characterized in that it comprises a computer as a control unit and the Rühreintrag and optionally the temperature of the vessel are computer controlled.
7. Vorrichtung nach Anspruch 6, dadurch gekennzeichnet, dass die kontinuierliche Aufzeichnung und gegebenenfalls Auswertung des Rühreintrags, der Temperatur und der Leitfähigkeit rechnergestützt erfolgt. 7. Apparatus according to claim 6, characterized in that the continuous recording and optionally evaluation of the Rühreintrags, the temperature and the conductivity is computer-aided.
8. Verwendung einer Vorrichtung nach einem der Ansprüche 1 bis 7 zur Bestimmung geeigneter Prozessparameter für die Herstellung von Emulsionen oder Dispersionen.8. Use of a device according to one of claims 1 to 7 for the determination of suitable process parameters for the preparation of emulsions or dispersions.
9. Verfahren zur Bestimmung geeigneter Prozessparameter für die Herstellung von Emulsionen oder Dispersionen, dadurch gekennzeichnet, dass in einer Vorrichtung gemäß einem der Ansprüche 1 bis 7 die Ausgangsstoffe der Emulsionen oder Dispersionen gemeinsam oder getrennt in das Gefäß eingeführt und unter Rühreintrag gemischt werden und der Rühreintrag, die Leitfähigkeit und die Temperatur kontinuierlich gemessen werden und in Abhängigkeit von den erhaltenen Messwerten gegebenenfalls der Rühreintrag und/oder die Temperatur des Gefäßes verändert werden.9. A method for determining suitable process parameters for the preparation of emulsions or dispersions, characterized in that in a device according to one of claims 1 to 7, the starting materials of the emulsions or dispersions are introduced jointly or separately into the vessel and mixed under stirring and mixing the stirring , the conductivity and the temperature are measured continuously and, depending on the measured values obtained, if appropriate, the stirring input and / or the temperature of the vessel are changed.
10. Verfahren nach Anspruch 9, dadurch gekennzeichnet, dass die zeitliche Veränderung der Leitfähigkeit bei unterschiedlichen Rühreinträgen oder in Abhängigkeit von Zugaben von Ausgangsstoffen der Emulsion oder Dispersion oder die Abhängigkeit der Leitfähigkeit von der Temperatur, gegebenenfalls bei unterschiedlichen Herstellungstemperaturen, bestimmt werden. 10. The method according to claim 9, characterized in that the temporal change in the conductivity at different Rühreinträgen or as a function of additions of starting materials of the emulsion or dispersion or the dependence of the conductivity of the temperature, optionally determined at different production temperatures.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2005/010480 WO2007036240A1 (en) | 2005-09-28 | 2005-09-28 | Device for on-line process control during the production of emulsions or dispersions |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1929271A1 true EP1929271A1 (en) | 2008-06-11 |
Family
ID=36387772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05792460A Withdrawn EP1929271A1 (en) | 2005-09-28 | 2005-09-28 | Device for on-line process control during the production of emulsions or dispersions |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080319582A1 (en) |
EP (1) | EP1929271A1 (en) |
JP (1) | JP2009509732A (en) |
CA (1) | CA2624165A1 (en) |
WO (1) | WO2007036240A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007060908A1 (en) * | 2007-12-14 | 2009-06-18 | Thermo Electron (Karlsruhe) Gmbh | Rotational rheometer and method for determining material properties with a rotational rheometer |
EP2123606A1 (en) | 2008-05-19 | 2009-11-25 | Kemira Pigments Oy | Ultrafine titanium dioxide nanoparticles and dispersions thereof |
CN104634966A (en) * | 2010-03-31 | 2015-05-20 | 积水医疗株式会社 | Method for avoiding influence of endogenous lipoprotein and reagent |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62277132A (en) * | 1986-05-23 | 1987-12-02 | Aikoushiya Seisakusho:Kk | Agitating device |
JPS63111927U (en) * | 1987-01-14 | 1988-07-19 | ||
FR2711800B1 (en) * | 1993-10-28 | 1996-01-12 | Agronomique Inst Nat Rech | Process and equipment for characterizing the stability of an emulsion. |
FR2737780B1 (en) * | 1995-08-11 | 1997-09-19 | Inst Francais Du Petrole | FLUID MIXTURE TEST CELL ADAPTED TO DETECT PHASE CHANGES |
DE19720911C1 (en) * | 1997-05-17 | 1998-08-13 | Grundig Ag | Viscometer for paint preparation |
FR2772129B1 (en) * | 1997-12-04 | 2000-02-25 | Didier Roux | APPARATUS AND METHODS FOR MEASUREMENT ON A FLOWING FLOW WITH SHEAR |
JP3507364B2 (en) * | 1999-07-08 | 2004-03-15 | キヤノン株式会社 | Developing device |
US6603315B2 (en) * | 2001-01-30 | 2003-08-05 | Ifac Gmbh & Co. Kg | Measuring probe, measuring instrument and method for determining the physical stability of emulsions and dispersions |
JP3469892B2 (en) * | 2002-02-25 | 2003-11-25 | クレーテ株式会社 | Tabletop vacuum emulsification equipment |
JP4559021B2 (en) * | 2002-12-02 | 2010-10-06 | 株式会社関口 | Mixing method |
US7775704B2 (en) * | 2003-03-21 | 2010-08-17 | Kemira Oyj | Device and method for continuously producing emulsions or dispersions |
JP2005007285A (en) * | 2003-06-19 | 2005-01-13 | Hitachi Ltd | Treatment apparatus of alkali metal-containing liquid and operation method therefor |
-
2005
- 2005-09-28 CA CA002624165A patent/CA2624165A1/en not_active Abandoned
- 2005-09-28 WO PCT/EP2005/010480 patent/WO2007036240A1/en active Application Filing
- 2005-09-28 JP JP2008532602A patent/JP2009509732A/en active Pending
- 2005-09-28 US US12/088,327 patent/US20080319582A1/en not_active Abandoned
- 2005-09-28 EP EP05792460A patent/EP1929271A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2007036240A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20080319582A1 (en) | 2008-12-25 |
JP2009509732A (en) | 2009-03-12 |
CA2624165A1 (en) | 2007-04-05 |
WO2007036240A1 (en) | 2007-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1606044B2 (en) | Device and method for continuously producing emulsions or dispersions | |
EP0605497B2 (en) | Medication vehicles made of solid lipid particles (solid lipid nanospheres - sln) | |
EP1194123B1 (en) | Method for controlled production of ultrafine microparticles and nanoparticles | |
CA2623112C (en) | Method for producing ultrafine submicronic suspensions | |
EP1868574B1 (en) | Method for producing ultrafine particle suspensions under mild conditions, ultrafine particles and use thereof | |
EP1176949A2 (en) | Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same | |
EP2412431A1 (en) | Dispersion and manufacturing method therefor | |
Zielińska et al. | Solid lipid nanoparticles and nanostructured lipid carriers as novel carriers for cosmetic ingredients | |
DE10312763A1 (en) | Process for the preparation of an SLN dispersion | |
DE69824315T2 (en) | METHOD FOR CHARACTERIZING COMPLEX LIQUIDS AND DEVICES FOR IMPLEMENTING THE PROCESS | |
EP1929271A1 (en) | Device for on-line process control during the production of emulsions or dispersions | |
DE202005015341U1 (en) | In-line-process control device for use during production of e.g. oil-in-water emulsion, comprises measuring probe providing continuous measurement of temperature and conductivity of emulsion or dispersion | |
EP1707256B1 (en) | Device and method for continuously producing emulsions or dispersions | |
DE102005017777A1 (en) | Preparation of high fine particle suspension comprises dissolving solid in a solvent, freezing, lyophilizing solid matrix, withdrawing solid matrix from solvent and dispersing in an external phase and applying high power on the dispersion | |
KR20200034631A (en) | Ultrasound-Assisted Delivery System using Microcapsule Platform Containing Nanobubbles and Drugs | |
DE19945203A1 (en) | Lipid particles based on matrix comprising solid and liquid lipid, useful in diagnostics and for controlled release of active agents, especially pharmaceuticals | |
KR20060004918A (en) | Device and method for continuously producing emulsions or dispersions | |
Mustafa et al. | Formulation Techniques, Characterization of Nanoemulsion and their Pharmaceutical Applications: A Comprehensive Technical Review | |
KR20090010153A (en) | Device for in-line process control during the production of emulsions or dispersions | |
Grossmann | Influence of manufacturing process parameters on the physical properties of an oil-in-water cream |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080408 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: KEMIRA OYJ |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130403 |